{"content":"<li class=\"n-box-item date-title\" data-end=\"1553745599\" data-start=\"1553659200\" data-txt=\"Monday, December 23, 2019\">Wednesday, March 27, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3446315\" data-ts=\"1553740554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ODP\" target=\"_blank\">ODP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446315-office-depotminus-3_5-after-settling-ftc-allegations-of-computer-repair-deception\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Office Depot -3.5% after settling FTC allegations of computer repair deception</a></h4><ul><li>Office Depot (NASDAQ:<a href='https://seekingalpha.com/symbol/ODP' title='Office Depot, Inc.'>ODP</a>) <font color=\"red\">-3.5%</font> after-hours as the Federal Trade Commission said the company <a href=\"https://www.ftc.gov/news-events/press-releases/2019/03/office-depot-tech-support-firm-will-pay-35-million-settle-ftc\" target=\"_blank\">agreed to pay a $25M fine</a> to settle allegations that it tricked consumers into buying costly computer repair services.</li><li>ODP and software supplier Support.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SPRT' title='Support.com, Inc.'>SPRT</a>), which agreed to pay $10M, allegedly deceived customers by claiming their software had found malware symptoms on their computers, the FTC said.</li><li>The companies used free PC check-up services that claimed to scan customers computers for viruses and other security threats but actually triggered a deceptive report of malware when the customers checked \"yes\" to one of four questions asked at the beginning of the check-up; the companies would then recommend services that could cost hundreds of dollars to fix the problems, the FTC said.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446315\" data-linked=\"Office Depot -3.5% after settling FTC allegations of computer repair deception\" data-tweet=\"$ODP $SPRT - Office Depot -3.5% after settling FTC allegations of computer repair deception https://seekingalpha.com/news/3446315-office-depotminus-3_5-after-settling-ftc-allegations-of-computer-repair-deception?source=tweet\" data-url=\"https://seekingalpha.com/news/3446315-office-depotminus-3_5-after-settling-ftc-allegations-of-computer-repair-deception\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446313\" data-ts=\"1553735259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STIM\" target=\"_blank\">STIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446313-neuronetics-up-5-after-hours-on-neurostar-reimbursement-japan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neuronetics up 5% after hours on NeuroStar reimbursement Japan</a></h4><ul><li>Neuronetics (NASDAQ:<a href='https://seekingalpha.com/symbol/STIM' title='Neuronetics, Inc.'>STIM</a>) is up <font color=\"green\">5%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17457426-neurostar-advanced-therapy-receive-reimbursement-approval-japan\" target=\"_blank\">announcement </a>that Japan's Central Social Insurance Medical Council has approved reimbursement for NeuroStar Advanced Therapy for major depressive disorder in adults.</li><li>Reimbursement of ¥12,000 per session will go into effect on or about June 1.</li><li>Teijin Pharma Limited is the exclusive in-country distributor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446313\" data-linked=\"Neuronetics up 5% after hours on NeuroStar reimbursement Japan\" data-tweet=\"$STIM - Neuronetics up 5% after hours on NeuroStar reimbursement Japan https://seekingalpha.com/news/3446313-neuronetics-up-5-after-hours-on-neurostar-reimbursement-japan?source=tweet\" data-url=\"https://seekingalpha.com/news/3446313-neuronetics-up-5-after-hours-on-neurostar-reimbursement-japan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446308\" data-ts=\"1553724150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARA\" target=\"_blank\">ARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446308-american-renal-associates-cfo-resigns-amid-audit-work\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Renal Associates CFO resigns amid audit work</a></h4><ul>   <li>Along with <a href=\"https://seekingalpha.com/news/3446286-american-renal-restate-financials-shares-7-percent-hours\" target=\"_blank\">restating its financials</a> for several years, American Renal Associates (NYSE:<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings, Inc.'>ARA</a>) says its chief financial officer Jason Boucher has <a href=\"https://seekingalpha.com/pr/17457419-american-renal-associates-holdings-inc-provides-update-audit-committee-review-announces\" target=\"_blank\">resigned</a>.</li>    <li>Mark Herbers will serve as interim chief financial officer and interim chief accounting officer. The company will conduct a search for permanent replacements for both roles.</li>    <li>Shares are now <font color=\"red\">down 18.6%</font> postmarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446308\" data-linked=\"American Renal Associates CFO resigns amid audit work\" data-tweet=\"$ARA - American Renal Associates CFO resigns amid audit work https://seekingalpha.com/news/3446308-american-renal-associates-cfo-resigns-amid-audit-work?source=tweet\" data-url=\"https://seekingalpha.com/news/3446308-american-renal-associates-cfo-resigns-amid-audit-work\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446302\" data-ts=\"1553722288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446302-pvh-lulu-odp-and-nlsn-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PVH, LULU, ODP and NLSN among notable after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a> <font color=\"green\">+10%</font>. <a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color=\"green\">+9.3%</font>. <a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color=\"green\">+7.9%</font>. <a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a> <font color=\"green\">+4.7%</font>. <a href='https://seekingalpha.com/symbol/ETCG' title='Grayscale Ethereum Classic Trust &#40;ETC&#41;'>OTCQX:ETCG</a> <font color=\"green\">+4.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings plc'>NLSN</a> <font color=\"red\">-10.3%</font>. <a href='https://seekingalpha.com/symbol/ODP' title='Office Depot, Inc.'>ODP</a> <font color=\"red\">-6.6%</font>. <a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a> <font color=\"red\">-5.4%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings, Inc.'>SENS</a> <font color=\"red\">-3.5%</font>. <a href='https://seekingalpha.com/symbol/PBR' title='Petróleo Brasileiro S.A. - Petrobras'>PBR</a> <font color=\"red\">-2.8%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3446302\" data-linked=\"PVH, LULU, ODP and NLSN among notable after hours movers\" data-tweet=\"$PVH $LULU $VRNT - PVH, LULU, ODP and NLSN among notable after hours movers https://seekingalpha.com/news/3446302-pvh-lulu-odp-and-nlsn-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446302-pvh-lulu-odp-and-nlsn-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446286\" data-ts=\"1553719930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARA\" target=\"_blank\">ARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446286-american-renal-to-restate-financials-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Renal to restate financials; shares down 7% after hours</a></h4><ul><li>American Renal Associates (NYSE:<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings, Inc.'>ARA</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1498068/000149806819000019/form8-kmarchannouncement.htm\" target=\"_blank\">discloses </a>that its Audit Committee has determined that its financial statements for fiscal years 2014, 2015, 2016, 2017 and the first three quarters of 2018 can no longer be relied upon due to deficiencies in revenue recognition, collections and related matters and internal controls over financial reporting.</li><li>Specifically, the company says it failed to appropriately reconcile its contractual allowance estimates for discounts and price concessions with cash subsequently received in prior period patient claims. It also failed to create a reserve for uncollectible accounts across its payer groups.</li><li>Management expects the overall cumulative impact of these issues on operating and pre-tax income over the non-reliance periods (2014 onward) will be between -$5M and +$5M.</li><li>The cumulative estimated impact on 2018 operating income and pre-tax income should be negative $13M - 23M (before presentation of net income attributable to noncontrolling interests).</li><li>Shares are down <font color=\"red\">7%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446286\" data-linked=\"American Renal to restate financials; shares down 7% after hours\" data-tweet=\"$ARA - American Renal to restate financials; shares down 7% after hours https://seekingalpha.com/news/3446286-american-renal-to-restate-financials-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3446286-american-renal-to-restate-financials-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446279\" data-ts=\"1553719321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446279-on-semi-acquires-quantenna-for-1_07b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ON Semi acquires Quantenna for $1.07B</a></h4><ul><li><strong>Update:</strong> Quantenna resumes trading and is <font color=\"green\">up 18%</font> to $24.28.</li><li>ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) will acquire wi-fi tech and software company Quantenna Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/QTNA' title='Quantenna Communications, Inc.'>QTNA</a>) for $24.50 per share in an all cash transaction, representing an equity value of $1.07B.</li><li>Enterprise value is $936M after accounting for Quantenna's cash on hand at the end of Q4.</li><li>Following the deal close, ON expects the acquisition to be immediately accretive to non-GAAP EPS and FCF.</li><li>The deal is expected to close in 2H.</li><li>ON shares are<font color=\"green\"> </font><font color=\"green\">up 1.2%</font> after hours to $20.81. QTNA shares were halted ahead of the announcement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446279\" data-linked=\"ON Semi acquires Quantenna for $1.07B\" data-tweet=\"$ON $ON $QTNA - ON Semi acquires Quantenna for $1.07B https://seekingalpha.com/news/3446279-on-semi-acquires-quantenna-for-1_07b?source=tweet\" data-url=\"https://seekingalpha.com/news/3446279-on-semi-acquires-quantenna-for-1_07b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446272\" data-ts=\"1553718842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446272-pvhplus-7-after-earnings-shine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PVH +7% after earnings shine</a></h4><ul><li>PVH (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>) jumps <font color=\"green\">6.55%</font> after topping estimates on both lines of its Q4 report.</li><li>CEO summary: \"Tommy Hilfiger had an outstanding quarter, with strong growth across all product categories and regions. Calvin Klein delivered a healthy quarter, with particular strength in Europe, solidifying our confidence in the margin opportunity that we previously identified for 2019 and beyond. The outperformance against our guidance in the Tommy Hilfiger and Calvin Klein businesses was partially offset by weaker trends in our Heritage Brands business.\u201d</li><li>Looking ahead, the apparel company anticipates FY20 revenue of $10.04B vs. $9.90B consensus and FY20 EPS of $10.30 to $10.40 vs. $10.33 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446256-phillips-van-heusen-beats-0_08-beats-revenue\" target=\"_blank\">Phillips-Van Heusen beats by $0.08, beats on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446272\" data-linked=\"PVH +7% after earnings shine\" data-tweet=\"$PVH - PVH +7% after earnings shine https://seekingalpha.com/news/3446272-pvhplus-7-after-earnings-shine?source=tweet\" data-url=\"https://seekingalpha.com/news/3446272-pvhplus-7-after-earnings-shine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446270\" data-ts=\"1553718742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446270-nielsenminus-10-on-report-blackstones-out-of-auction-for-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen -10% on report Blackstone&#39;s out of auction for company</a></h4><ul>   <li>Nielsen Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings plc'>NLSN</a>) has <font color=\"red\">slid 10%</font> after hours as the <i>New York Post</i> reports have Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>) <a href=\"https://nypost.com/2019/03/27/blackstone-backs-out-of-auction-to-buy-ratings-giant-nielsen-sources/\" target=\"_blank\">dropping out of an auction</a> for the company.</li>    <li>Apollo Global Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>) is also losing interest in the bidding, according to the report.</li>    <li>With those two as the strongest bidders, it throws Nielsen's entire sales process into doubt. The company has debt of about $8B vs. a market cap of $9.4B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446270\" data-linked=\"Nielsen -10% on report Blackstone&#39;s out of auction for company\" data-tweet=\"$NLSN $BX $APO - Nielsen -10% on report Blackstone&#39;s out of auction for company https://seekingalpha.com/news/3446270-nielsenminus-10-on-report-blackstones-out-of-auction-for-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3446270-nielsenminus-10-on-report-blackstones-out-of-auction-for-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446266\" data-ts=\"1553718473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446266-eyepoint-pharma-down-8-after-hours-on-planned-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyePoint Pharma down 8% after hours on planned equity offering</a></h4><ul><li>EyePoint Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a>) slips <font color=\"red\">8%</font> after in reaction to its planned <a href=\"https://seekingalpha.com/pr/17457412-eyepoint-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446266\" data-linked=\"EyePoint Pharma down 8% after hours on planned equity offering\" data-tweet=\"$EYPT - EyePoint Pharma down 8% after hours on planned equity offering https://seekingalpha.com/news/3446266-eyepoint-pharma-down-8-after-hours-on-planned-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3446266-eyepoint-pharma-down-8-after-hours-on-planned-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446265\" data-ts=\"1553718240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446265-verintplus-8_8-on-upside-raised-outlooks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint +8.8% on upside, raised outlooks</a></h4><ul><li>Verint Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a>) <font color=\"green\">gains 8.8% </font>after a Q4 EPS miss with a slight revenue miss. Upside Q1 guidance has revenue at $315.4M (consensus: $310.69M) and EPS growth of 14% Y/Y.</li><li>The raised FY20 outlook has revenue at $1.37B (consensus: $1.33B) and EPS of $3.60 (consensus: $3.52).</li><li>Earnings call starts at 4:30 PM with a webcast available <a href=\"https://www.verint.com/\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17457397-verint-announces-strong-fy2019-results-raises-guidance-fy2020\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446246-verint-systems-beats-0_07-misses-revenue\" target=\"_blank\">Verint Systems beats by $0.07, misses on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446265\" data-linked=\"Verint +8.8% on upside, raised outlooks\" data-tweet=\"$VRNT - Verint +8.8% on upside, raised outlooks https://seekingalpha.com/news/3446265-verintplus-8_8-on-upside-raised-outlooks?source=tweet\" data-url=\"https://seekingalpha.com/news/3446265-verintplus-8_8-on-upside-raised-outlooks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446264\" data-ts=\"1553718197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446264-blueprint-medicines-to-accelerate-pipeline-300m-capital-raise-initiated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint Medicines to accelerate pipeline; $300M capital raise initiated</a></h4><ul><li>Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines Corporation'>BPMC</a>) <a href=\"https://seekingalpha.com/pr/17457373-blueprint-medicines-announces-accelerated-regulatory-submission-plans-recent-clinical\" target=\"_blank\">announces </a>plans to speed development of pipeline candidates avapritinib, BLU-667 and BLU-782.</li><li>Avapritinib: marketing applications will be filed in the U.S. next quarter and in Europe in Q3 for PDGFRα D842V mutant gastrointestinal stromal tumors &#40;GIST&#41; and fourth-line GIST. U.S. marketing application for advanced stromal tumors to be filed in Q1 2020 (assuming agreement with the FDA on the necessary clinical data).</li><li>BLU-667: enrollment target in registration study , ARROW, has been reached in the RET-fusion non-small cell lung cancer &#40;NSCLC&#41; arm and will be reached next quarter in the RET-fusion medullary thyroid cancer &#40;MTC&#41; arm. The company expects to file a U.S. marketing application in Q1 2020 for NSCLC patients who have been previously treated with platinum-based chemo, followed by an application in late Q2 for patients with RET-mutant MTC who have previously received a multikinase inhibitor.</li><li>BLU-782: a Phase 2a study in fibrodysplasia ossificans progressiva &#40;FOP&#41; will launch in Q4.</li><li>The company has <a href=\"https://seekingalpha.com/pr/17457390-blueprint-medicines-announces-proposed-public-offering-shares-common-stock\" target=\"_blank\">launched </a>a $300M public offering of common stock. Price, volume and terms have yet to be released. Net proceeds will fund product development and the buildout of its commercial infrastructure.</li><li>Shares are down <font color=\"red\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446264\" data-linked=\"Blueprint Medicines to accelerate pipeline; $300M capital raise initiated\" data-tweet=\"$BPMC - Blueprint Medicines to accelerate pipeline; $300M capital raise initiated https://seekingalpha.com/news/3446264-blueprint-medicines-to-accelerate-pipeline-300m-capital-raise-initiated?source=tweet\" data-url=\"https://seekingalpha.com/news/3446264-blueprint-medicines-to-accelerate-pipeline-300m-capital-raise-initiated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446256\" data-ts=\"1553717857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446256-phillips-van-heusen-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips-Van Heusen beats by $0.08, beats on revenue</a></h4><ul><li>Phillips-Van Heusen (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>): Q4 Non-GAAP EPS of $1.84 <span style=\"color:green\">beats by $0.08</span>; GAAP EPS of $2.09.</li><li>Revenue of $2.48B (-0.8% Y/Y) <font color=\"green\">beats by $70M</font>.</li><li>Shares <font color=\"green\">+6.4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17457421-pvh-corp-reports-2018-fourth-quarter-full-year-results-provides-2019-outlook\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3446256\" data-linked=\"Phillips-Van Heusen beats by $0.08, beats on revenue\" data-tweet=\"$PVH - Phillips-Van Heusen beats by $0.08, beats on revenue https://seekingalpha.com/news/3446256-phillips-van-heusen-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3446256-phillips-van-heusen-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446255\" data-ts=\"1553717773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446255-lululemonplus-10-after-strong-sales-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon +10% after strong sales report</a></h4><ul><li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) rallies in AH trading after posting strong sales in Q4 and setting strong guidance.</li><li>Comparable sales were up 17.0% during the quarter to edge past the high-flying consensus mark of +16.6% and fall comfortably in management's guidance range. LULU's stores turned in a +6% comp for the quarter.</li><li>Looking ahead, the retailer expects FY20 revenue of $3.70B to $3.74B vs. $3.71B consensus and EPS of $4.48 to $4.55 vs $4.40 consensus.</li><li>LULU <font color=\"green\">+9.64%</font> AH to $161.02.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446242-lululemon-athletica-beats-0_10-beats-revenue\" target=\"_blank\">Lululemon Athletica beats by $0.10, beats on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446255\" data-linked=\"Lululemon +10% after strong sales report\" data-tweet=\"$LULU - Lululemon +10% after strong sales report https://seekingalpha.com/news/3446255-lululemonplus-10-after-strong-sales-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3446255-lululemonplus-10-after-strong-sales-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446247\" data-ts=\"1553717409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446247-comparable-sales-up-4-five-below\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comparable sales up 4% at Five Below</a></h4><ul><li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below, Inc.'>FIVE</a>) trades slightly lower after spilling Q4 numbers.</li><li>Comparable sales rose 4.4% during the <a href=\"https://seekingalpha.com/pr/17457378-five-inc-announces-fourth-quarter-fiscal-2018-financial-results\" target=\"_blank\">quarter</a> and total sales were up 19.4% with five new stores (net) in the mix from a year ago.</li><li>Operating income rose 12.6% to $117M.</li><li>Looking ahead, the retailer expects Q1 revenue of $361M to $366M vs. $363M consensus based on opening approximately 35 new stores and assuming a 3% to 4% increase in comparable sales. Net income is expected to fall in a range of $18.0M to $19.7M and EPS of $0.32 to $0.35 is anticipated vs. $0.40 consensus.</li><li>FIVE <font color=\"red\">-0.33%</font> AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446239-five-inc-eps-line-beats-revenue\" target=\"_blank\">Five Below, Inc. EPS in-line, beats on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446247\" data-linked=\"Comparable sales up 4% at Five Below\" data-tweet=\"$FIVE - Comparable sales up 4% at Five Below https://seekingalpha.com/news/3446247-comparable-sales-up-4-five-below?source=tweet\" data-url=\"https://seekingalpha.com/news/3446247-comparable-sales-up-4-five-below\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446242\" data-ts=\"1553717223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446242-lululemon-athletica-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon Athletica beats by $0.10, beats on revenue</a></h4><ul><li>Lululemon Athletica (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>): Q4 Non-GAAP EPS of $1.85 <span style=\"color:green\">beats by $0.10</span>; GAAP EPS of $1.65.</li><li>Revenue of $1.17B (+26.0% Y/Y) <font color=\"green\">beats by $20M</font>.</li><li>Shares <font color=\"green\">+7.4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17457393-lululemon-athletica-inc-announces-fourth-quarter-full-year-fiscal-2018-results-board\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3446242\" data-linked=\"Lululemon Athletica beats by $0.10, beats on revenue\" data-tweet=\"$LULU - Lululemon Athletica beats by $0.10, beats on revenue https://seekingalpha.com/news/3446242-lululemon-athletica-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3446242-lululemon-athletica-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446233\" data-ts=\"1553716379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446233-amarin-up-3-on-addition-of-vascepa-to-soc-guidelines-for-diabetes-related-cv-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin up 3% on addition of Vascepa to SOC guidelines for diabetes-related CV risk</a></h4><ul><li>Amarin (<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a> <font color=\"green\">+3%</font>) is up on modestly higher volume following an <a href=\"https://seekingalpha.com/pr/17457221-american-diabetes-association-issues-critical-updates-2019-standards-medical-care-diabetes\" target=\"_blank\">announcement </a>from the American Diabetes Association adding Vascepa (icosapent ethyl) to its standard-of-care recommendation to reduce cardiovascular &#40;CV&#41; risk in diabetics with atherosclerotic CV disease or other risk factors who have have elevated triglycerides and are currently on statin therapy with controlled \"bad\" cholesterol.</li><li>The ADA made the change based on the results from the <a href=\"https://clinicaltrials.gov/ct2/show/NCT01492361?term=reduce-it&amp;rank=1\" target=\"_blank\">REDUCE-IT</a> study.</li><li>It also updated its guidelines to include the beneficial effects of AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"red\">-0.7%</font>) Farxiga (dapagliflozin) on reducing hospitalization for heart failure and the progression of chronic kidney disease, including a lower level of kidney function to qualify for treatment (greater than or equal to 45 mL/min 1.73 m2 from greater than or equal to 60 mL/min/1.73 m2).</li><li>The changes should make it easier for both products to make it onto payers' formularies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446233\" data-linked=\"Amarin up 3% on addition of Vascepa to SOC guidelines for diabetes-related CV risk\" data-tweet=\"$AMRN $AZN - Amarin up 3% on addition of Vascepa to SOC guidelines for diabetes-related CV risk https://seekingalpha.com/news/3446233-amarin-up-3-on-addition-of-vascepa-to-soc-guidelines-for-diabetes-related-cv-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3446233-amarin-up-3-on-addition-of-vascepa-to-soc-guidelines-for-diabetes-related-cv-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>104&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446230\" data-ts=\"1553715272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446230-canopy-growth-teams-up-seth-rogen-cannabis-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth teams up with Seth Rogen cannabis venture</a></h4><ul><li>Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"red\">-4.2%</font>) has taken a <a href=\"https://seekingalpha.com/pr/17456317-canopy-growth-welcomes-houseplant-family\" target=\"_blank\">minority stak</a>e in a cannabis venture founded by actor Seth Rogen and his long-time friend, director and producer Evan Goldberg.</li><li>The company will supply and distribute the venture's cannabis products, branded as Houseplant, throughout Canada.</li><li>Financial terms remain confidential.</li><li>Other cannabis producers are down as well, in apparent response to New Jersey's <a href=\"https://seekingalpha.com/news/3445726-new-jersey-delays-vote-legal-weed\" target=\"_blank\">decision </a>to delay its vote on legal weed.</li><li>Selected tickers: Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"red\">-3.1%</font>); Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"red\">-10.5%</font>); Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-3.9%</font>)</li><li>ETFs: Alternative Harvest (<a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a> <font color=\"red\">-3.3%</font>); Global X Fertilizer/Potash (<a href='https://seekingalpha.com/symbol/SOIL' title='Global X Fertilizers/Potash ETF'>SOIL</a> <font color=\"green\">+0.3%</font>); AdvisorShares Vice (<a href='https://seekingalpha.com/symbol/ACT' title='AdvisorShares Vice ETF'>ACT</a> <font color=\"red\">-1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446230\" data-linked=\"Canopy Growth teams up with Seth Rogen cannabis venture\" data-tweet=\"$CGC $TLRY $CRON - Canopy Growth teams up with Seth Rogen cannabis venture https://seekingalpha.com/news/3446230-canopy-growth-teams-up-seth-rogen-cannabis-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3446230-canopy-growth-teams-up-seth-rogen-cannabis-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446229\" data-ts=\"1553714606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446229-chips-cloud-keep-tech-in-red\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chips, cloud keep tech in the red</a></h4><ul><li>The tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) heads towards today's close <font color=\"red\">down 0.7% </font>with the Philadelphia Semiconductor Index <font color=\"red\">down 1.8% </font>and the tech-heavy Nasdaq 100 trailing <font color=\"red\">0.7%</font>.</li><li>Chips slid after German peer Infineon cut its revenue guidance for the year. Cloud stocks dropped on a combination of the lawsuit against Salesforce by trafficking victims and the general market dip.</li><li>The S&amp;P 500 is <font color=\"red\">down 0.5%</font> and the Nasdaq is <font color=\"red\">down 0.8%</font>.</li><li>Related broad tech ETFs: <a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>, <a href='https://seekingalpha.com/symbol/VGT' title='Vanguard Information Technology ETF'>VGT</a>, <a href='https://seekingalpha.com/symbol/TECL' title='Direxion Technology Bull 3x Shares ETF'>TECL</a>, <a href='https://seekingalpha.com/symbol/FTEC' title='Fidelity MSCI Information Technology Index ETF'>FTEC</a>, <a href='https://seekingalpha.com/symbol/IYW' title='iShares U.S. Technology ETF'>IYW</a>, <a href='https://seekingalpha.com/symbol/ROM' title='ProShares Ultra Technology ETF'>ROM</a>, <a href='https://seekingalpha.com/symbol/QTEC' title='First Trust NASDAQ-100-Tech Index ETF'>QTEC</a>, <a href='https://seekingalpha.com/symbol/RYT' title='Invesco S&P 500 Equal Weight Technology ETF'>RYT</a>, <a href='https://seekingalpha.com/symbol/FNG' title='AdvisorShares New Tech and Media ETF'>FNG</a>, <a href='https://seekingalpha.com/symbol/TECS' title='Direxion Technology Bear 3x Shares ETF'>TECS</a>, <a href='https://seekingalpha.com/symbol/IGM' title='iShares North American Tech ETF'>IGM</a>, <a href='https://seekingalpha.com/symbol/FXL' title='First Trust Tech AlphaDEX ETF'>FXL</a>, <a href='https://seekingalpha.com/symbol/XNTK' title='SPDR NYSE Technology ETF'>XNTK</a>, <a href='https://seekingalpha.com/symbol/REW' title='ProShares UltraShort Technology ETF'>REW</a>, <a href='https://seekingalpha.com/symbol/JHMT' title='John Hancock Multifactor Technology ETF'>JHMT</a>, <a href='https://seekingalpha.com/symbol/XITK' title='SPDR Innovative Technology ETF'>XITK</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3446167-u-s-semis-slide-infineon-forecast-cut\" target=\"_blank\">U.S. semis slide on Infineon forecast cut</a> (March 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446205-cloud-stocks-slide-market-dip\" target=\"_blank\">Cloud stocks slide on market dip</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446229\" data-linked=\"Chips, cloud keep tech in the red\" data-tweet=\"$XLK $VGT $TECL - Chips, cloud keep tech in the red https://seekingalpha.com/news/3446229-chips-cloud-keep-tech-in-red?source=tweet\" data-url=\"https://seekingalpha.com/news/3446229-chips-cloud-keep-tech-in-red\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446223\" data-ts=\"1553713117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446223-jack-in-box-rallies-after-gordon-haskett-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jack in the Box rallies after Gordon Haskett upgrade</a></h4><ul> <li>Jack in the Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack in the Box Inc.'>JACK</a>) is <font color=\"green\">up 2.40%</font> after Gordon Haskett calls out the \"compelling\" risk/reward profile on the restaurant stock.</li> <li>Analyst Jeff Farmer thinks JACK is at a same-store sales inflection point and notes the low Street expectations for 2021 and 2022.</li><li>He also thinks shares are safe from a M&amp;A announcement letdown. \"We believe that any potential board of directors announcement that the company is suspending the sale process would be met with a muted market reaction given that JACK\u2019s current share price is well below pre-takeout speculation levels and valuation is at an 18-month low on an EV/EBITDA basis and three-year low on a P/E basis,\" he writes.</li> <li>Gordon Haskett moves to a Buy rating on JACK from Hold and assigns a price target of $91 (12.5X the 2020 EBITDA estimate). The PT is slightly below JACK's 52-week high of $93.98.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446223\" data-linked=\"Jack in the Box rallies after Gordon Haskett upgrade\" data-tweet=\"$JACK - Jack in the Box rallies after Gordon Haskett upgrade https://seekingalpha.com/news/3446223-jack-in-box-rallies-after-gordon-haskett-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3446223-jack-in-box-rallies-after-gordon-haskett-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446220\" data-ts=\"1553712817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446220-creative-realities-leads-technology-gainers-inpixon-and-dropcar-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Creative Realities leads technology gainers; Inpixon and DropCar among losers</a></h4><ul><li><b>Gainers:</b> Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"green\">+17%</font>. GSE Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc.'>GVP</a>) <font color=\"green\">+9%</font>. Sonic Foundry (<a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTCPK:SOFO</a>) <font color=\"green\">+9%</font>. UP Fintech Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TIGR' title='UP Fintech Holding Limited'>TIGR</a>) <font color=\"green\">+7%</font>. iCAD (NASDAQ:<a href='https://seekingalpha.com/symbol/ICAD' title='iCAD, Inc.'>ICAD</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"red\">-44%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-31%</font>. DropCar (NASDAQ:<a href='https://seekingalpha.com/symbol/DCAR' title='DropCar, Inc.'>DCAR</a>) <font color=\"red\">-29%</font>. CounterPath (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"red\">-21%</font>. SecureWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446220\" data-linked=\"Creative Realities leads technology gainers; Inpixon and DropCar among losers\" data-tweet=\"$CREX $GVP $SOFO - Creative Realities leads technology gainers; Inpixon and DropCar among losers https://seekingalpha.com/news/3446220-creative-realities-leads-technology-gainers-inpixon-and-dropcar-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446220-creative-realities-leads-technology-gainers-inpixon-and-dropcar-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446213\" data-ts=\"1553711995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446213-synaptics-accept-dialog-offer-needham\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics could accept Dialog offer - Needham</a></h4><ul><li>Needham analyst Rajvindra Gill thinks Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) \"would be more willing to accept\" an acquisition offer from Dialog (<a href='https://seekingalpha.com/symbol/DLGNF' title='Dialog Semiconductor Plc'>OTCPK:DLGNF</a>)  now after talks fell apart last summer.</li><li>Gill cites the \"vastly different\" Synaptics story with share price losses and exec departures.</li><li>Rating maintained at Buy with a $45 target.</li><li>SYNA shares are <font color=\"green\">up 1.8%</font> to $35.95.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445733-synaptics-plus-3_8-percent-m-chatter\" target=\"_blank\">Synaptics +3.8% on M&amp;A chatter</a> (March 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446213\" data-linked=\"Synaptics could accept Dialog offer - Needham\" data-tweet=\"$SYNA $DLGNF - Synaptics could accept Dialog offer - Needham https://seekingalpha.com/news/3446213-synaptics-accept-dialog-offer-needham?source=tweet\" data-url=\"https://seekingalpha.com/news/3446213-synaptics-accept-dialog-offer-needham\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446211\" data-ts=\"1553711862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446211-pg-and-e-gets-5_5b-in-funds-to-keep-operating-during-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E gets $5.5B in funds to keep operating during bankruptcy</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-2.2%</font>) <a href=\"https://www.mercurynews.com/2019/03/27/pge-lands-5-5-billion-in-funds-to-keep-operating-during-wildfire-linked-bankruptcy/\" target=\"_blank\">wins court approval for $5.5B in financing</a> to keep operating during its wildfire-linked bankruptcy case, a funding package the utility says is essential to continue basic electricity and gas operations.</li><li>The U.S. Bankruptcy Court in San Francisco approved the debtor-in-possession loan over objections from representatives of wildfire victims that wanted PG&amp;E to fund a program for housing, food and other necessities before obtaining the financing.</li><li>PG&amp;E filed for Chapter 11 bankruptcy protection in January following a string of devastating northern California wildfires, some linked to the company's equipment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446211\" data-linked=\"PG&amp;E gets $5.5B in funds to keep operating during bankruptcy\" data-tweet=\"$PCG - PG&amp;E gets $5.5B in funds to keep operating during bankruptcy https://seekingalpha.com/news/3446211-pg-and-e-gets-5_5b-in-funds-to-keep-operating-during-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3446211-pg-and-e-gets-5_5b-in-funds-to-keep-operating-during-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446210\" data-ts=\"1553711565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446210-jefferies-expects-tesla-to-rebound-after-rough-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies expects Tesla to rebound after rough Q1</a></h4><ul> <li>Jefferies anticipates Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+2.5%</font>) will post a modest loss of $50M in Q1 before running down a \"self-funded\" track for the remainder of the year.</li> <li>The firm keeps a Buy rating on Tesla and price target of <a href=\"https://www.barrons.com/articles/tesla-stock-is-facing-excessive-negativity-analyst-says-51553698750\" target=\"_blank\">$450</a> amid the \"excessive negativity\" it sees in the market over the name. Jefferies analyst Philippe Houchois notes shares of TSLA are back to support levels last tested in 2018 before Tesla had demonstrated profits and positive free cash flow.</li> <li>Across Wall Street, consensus estimates on Tesla for Q1 have been moving down, now standing at revenue of $6.09B and EPS of -$0.58.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446210\" data-linked=\"Jefferies expects Tesla to rebound after rough Q1\" data-tweet=\"$TSLA - Jefferies expects Tesla to rebound after rough Q1 https://seekingalpha.com/news/3446210-jefferies-expects-tesla-to-rebound-after-rough-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3446210-jefferies-expects-tesla-to-rebound-after-rough-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>294&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446207\" data-ts=\"1553710702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446207-boeing-jumps-after-unveiling-737-max-fix-safety-audits-show-no-added-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing jumps after unveiling 737 MAX fix, safety audits show no added concerns</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+1.4%</font>) pops higher after <a href=\"https://www.cnbc.com/2019/03/27/boeing-unveils-737-max-fixes-says-planes-are-safer.html\" target=\"_blank\">unveiling its software fix</a>, cockpit alerts and additional pilot training for its 737 MAX planes, saying the changes will boost the safety of the aircraft which has been involved in two deadly crashes since October.</li><li>Among the notable changes to MAX flight controls, the plane's MCAS automated flight control system will now receive data from both angle of attack sensors instead of just one.</li><li>Also, a Boeing official says the company\u2019s reviews of various flight control systems on new 737 MAX planes <a href=\"https://www.wsj.com/articles/boeing-reviews-more-737-max-systems-as-it-completes-software-update-11553709619\" target=\"_blank\">have not revealed any additional potential problems</a>.</li><li>The review has revisited analyses of potential hazards and malfunctions, and \"we have uncovered nothing that concerns us in any of those areas,\" the Boeing official said. \"Those reviews continue [and] they will continue for some time.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3446207\" data-linked=\"Boeing jumps after unveiling 737 MAX fix, safety audits show no added concerns\" data-tweet=\"$BA - Boeing jumps after unveiling 737 MAX fix, safety audits show no added concerns https://seekingalpha.com/news/3446207-boeing-jumps-after-unveiling-737-max-fix-safety-audits-show-no-added-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3446207-boeing-jumps-after-unveiling-737-max-fix-safety-audits-show-no-added-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>161&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446205\" data-ts=\"1553710466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446205-cloud-stocks-slide-on-market-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloud stocks slide on market dip</a></h4><ul><li>Cloud-related stocks are taking a beating today with no catalyst to move the sector. SecureWorks <a href=\"https://seekingalpha.com/news/3446007-secureworks-reports-mixed-q4-15m-repurchase-increase\" target=\"_blank\">reported earnings</a> this morning and Salesforce is <a href=\"https://seekingalpha.com/news/3446109-salesforce-minus-1_7-percent-suit-trafficking-victims\" target=\"_blank\">feeling pressure</a> from a lawsuit from trafficking victims, but the sector is likely swinging with the general market droop.</li><li>Movers include Domo (<a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a> <font color='red'>-8.4%</font>), Nutanix (<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix, Inc.'>NTNX</a> <font color='red'>-7.6%</font>), Zuora (<a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a> <font color='red'>-3.7%</font>), Twilio (<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio Inc.'>TWLO</a> <font color='red'>-4%</font>), Tableau (<a href='https://seekingalpha.com/symbol/DATA' title='Tableau Software, Inc.'>DATA</a> <font color='red'>-3.2%</font>), Appian (<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corporation'>APPN</a> <font color='red'>-2.8%</font>).</li><li>The S&amp;P 500 is <font color=\"red\">down 0.4%</font> and the Nasdaq <font color=\"red\">dips 0.6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446205\" data-linked=\"Cloud stocks slide on market dip\" data-tweet=\"$DOMO $NTNX $ZUO - Cloud stocks slide on market dip https://seekingalpha.com/news/3446205-cloud-stocks-slide-on-market-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3446205-cloud-stocks-slide-on-market-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446198\" data-ts=\"1553709839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446198-amyris-and-oil-states-international-among-energy-materials-gainers-transatlantic-petroleum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris and Oil States International among Energy/Materials gainers; TransAtlantic Petroleum and CARBO Ceramics among losers</a></h4><ul><li><b>Gainers: </b>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+22%</font>. Oil States International (NYSE:<a href='https://seekingalpha.com/symbol/OIS' title='Oil States International, Inc.'>OIS</a>) <font color=\"green\">+7%</font>. Venator Materials (NYSE:<a href='https://seekingalpha.com/symbol/VNTR' title='Venator Materials PLC'>VNTR</a>) <font color=\"green\">+6%</font>. Epsilon Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/EPSN' title='Epsilon Energy Ltd.'>EPSN</a>) <font color=\"green\">+6%</font>. NCS Multistage (NASDAQ:<a href='https://seekingalpha.com/symbol/NCSM' title='NCS Multistage Holdings, Inc.'>NCSM</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>TransAtlantic Petroleum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TAT' title='TransAtlantic Petroleum Ltd.'>TAT</a>) <font color=\"red\">-12%</font>. CARBO Ceramics (NYSE:<a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a>) <font color=\"red\">-10%</font>. OMNOVA Solutions (NYSE:<a href='https://seekingalpha.com/symbol/OMN' title='OMNOVA Solutions Inc.'>OMN</a>) <font color=\"red\">-7%</font>. SAExploration (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-7%</font>. Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446198\" data-linked=\"Amyris and Oil States International among Energy/Materials gainers; TransAtlantic Petroleum and CARBO Ceramics among losers\" data-tweet=\"$AMRS $OIS $VNTR - Amyris and Oil States International among Energy/Materials gainers; TransAtlantic Petroleum and CARBO Ceramics among losers https://seekingalpha.com/news/3446198-amyris-and-oil-states-international-among-energy-materials-gainers-transatlantic-petroleum?source=tweet\" data-url=\"https://seekingalpha.com/news/3446198-amyris-and-oil-states-international-among-energy-materials-gainers-transatlantic-petroleum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446196\" data-ts=\"1553709832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446196-aveo-up-19-on-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO up 19% on M&amp;A speculation</a></h4><ul><li>Nano cap AVEO Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color=\"green\">+19.4%</font>) is up on more than double normal volume. Earlier today, hedge fund manager BlueLion <a href=\"https://seekingalpha.com/instablog/47647843-thebluelion/5286356-astrazeneca-acquire-aveo-oncology\" target=\"_blank\">blogged </a>that, according to representatives from several investment banks, AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"red\">-0.8%</font>) will make a bid for the oncology player next quarter.</li><li>Shares have been range-bound since plummeting <font color=\"red\">40%</font> on January 31 when it <a href=\"https://seekingalpha.com/news/3428163-aveo-oncology-46-percent-delay-fotivda-nda-filing\" target=\"_blank\">announced </a>that it would not file its U.S. marketing application for kidney cancer med FOTIVDA (tivozanib) until it has more mature survival data.</li><li><strong>Update on 4/12:</strong> BlueLion has withdrawn the blog post suggesting M&amp;A chatter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446196\" data-linked=\"AVEO up 19% on M&amp;A speculation\" data-tweet=\"$AVEO $AZN - AVEO up 19% on M&amp;A speculation https://seekingalpha.com/news/3446196-aveo-up-19-on-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3446196-aveo-up-19-on-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446190\" data-ts=\"1553707384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITB\" target=\"_blank\">ITB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446190-homebuilders-come-on-strong-outlook-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilders come on strong as outlook improves</a></h4><ul><li>Homebuilder stocks climb after improving outlooks at KB Home and Lennar helped boost hopes for a brisk spring selling seasons.</li><li>The iShares U.S. Home Construction ETF (NYSE:<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>) <font color=\"green\">jumps 2.4%</font>; in the past five days, it's risen 3.7%, outperforming the S&amp;P 500, which fell 0.2% during the same period.</li><li>PulteGroup (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='green'>+5.1%</font>) advances the most, with William Lyon Homes (<a href='https://seekingalpha.com/symbol/WLH' title='William Lyon Homes'>WLH</a> <font color='green'>+4.5%</font>), Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color='green'>+4.3%</font>), and Beazer Homes (<a href='https://seekingalpha.com/symbol/BZH' title='Beazer Homes USA, Inc.'>BZH</a> <font color='green'>+4.9%</font>) also showing strong gains.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446001-lennar-saw-choppiness-q1-sees-housing-market-improving\" target=\"_blank\">Lennar saw \"choppiness\" in Q1 but sees housing market improving</a> (March 27)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a>, <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/PKB' title='Invesco Dynamic Building & Construction Portfolio ETF'>PKB</a>, <a href='https://seekingalpha.com/symbol/NAIL' title='Direxion Daily Homebuilders & Supplies Bull 3x Shares ETF'>NAIL</a>, <a href='https://seekingalpha.com/symbol/HOML' title='ETRACS Monthly Reset 2xLeveraged ISE Exclusively Homebuilders ETN'>HOML</a>, <a href='https://seekingalpha.com/symbol/HOMZ' title='Hoya Capital Housing ETF'>HOMZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3446190\" data-linked=\"Homebuilders come on strong as outlook improves\" data-tweet=\"$ITB $PHM $WLH - Homebuilders come on strong as outlook improves https://seekingalpha.com/news/3446190-homebuilders-come-on-strong-outlook-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3446190-homebuilders-come-on-strong-outlook-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446187\" data-ts=\"1553706592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446187-kb-homesplus-1_9-outlook-for-h2-brightens\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Homes +1.9% as outlook for H2 brightens</a></h4><ul><li>KB Home (NYSE:<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>)<font color=\"green\"> gains 1.9%</font> after<a href=\"https://seekingalpha.com/pr/17455984-kb-home-reports-2019-first-quarter-results\" target=\"_blank\"> fiscal Q1 EPS </a>of 31 cents beat the average analyst estimate of 25 cents and forecasts stronger revenue growth in H2 2019 on improving market conditions.</li><li>Q1 EPS compares with a loss of 82 cents in the year-ago quarter, which included a charge of $111.2M related to U.S. tax reform.</li><li>Q1 total revenue fell 7% Y/Y to $811.5M and average selling price slipped 5% to $370,900.</li><li>Q1 cancellation rate was flat at 20%.</li><li>Average community count rose 10% to 244.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445871-kb-home-beats-0_06-misses-revenue\" target=\"_blank\">KB Home beats by $0.06, misses on revenue</a>(March 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446187\" data-linked=\"KB Homes +1.9% as outlook for H2 brightens\" data-tweet=\"$KBH - KB Homes +1.9% as outlook for H2 brightens https://seekingalpha.com/news/3446187-kb-homesplus-1_9-outlook-for-h2-brightens?source=tweet\" data-url=\"https://seekingalpha.com/news/3446187-kb-homesplus-1_9-outlook-for-h2-brightens\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446185\" data-ts=\"1553706081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446185-lennar-and-orion-group-holdings-among-industrial-gainers-comstock-holding-and-trex-company-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennar and Orion Group Holdings among industrial gainers; Comstock Holding and Trex Company in losers</a></h4><ul><li><b>Gainers: </b>Jewett-Cameron Trading Company (NASDAQ:<a href='https://seekingalpha.com/symbol/JCTCF' title='Jewett-Cameron Trading Company Ltd.'>JCTCF</a>) <font color=\"green\">+10%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"green\">+8%</font>. Attis Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/ATIS' title='Attis Industries, Inc.'>ATIS</a>) <font color=\"green\">+7%</font>. Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+6%</font>. Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Comstock Holding Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/CHCI' title='Comstock Holding Companies, Inc.'>CHCI</a>) <font color=\"red\">-7%</font>. Trex Company (NYSE:<a href='https://seekingalpha.com/symbol/TREX' title='Trex Company, Inc.'>TREX</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446185\" data-linked=\"Lennar and Orion Group Holdings among industrial gainers; Comstock Holding and Trex Company in losers\" data-tweet=\"$JCTCF $ATIS $ORN - Lennar and Orion Group Holdings among industrial gainers; Comstock Holding and Trex Company in losers https://seekingalpha.com/news/3446185-lennar-and-orion-group-holdings-among-industrial-gainers-comstock-holding-and-trex-company-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3446185-lennar-and-orion-group-holdings-among-industrial-gainers-comstock-holding-and-trex-company-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446183\" data-ts=\"1553705763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446183-hexindai-leads-financial-gainers-china-bat-group-and-banco-macro-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hexindai leads financial gainers; China Bat Group and Banco Macro among losers</a></h4><ul><li><b>Gainers:</b> Hexindai (NASDAQ:<a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a>) <font color=\"green\">+10%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management Inc.'>MDLY</a>) <font color=\"green\">+9%</font>. Xenia Hotels &amp; Resorts (NYSE:<a href='https://seekingalpha.com/symbol/XHR' title='Xenia Hotels & Resorts, Inc.'>XHR</a>) <font color=\"green\">+8%</font>. LGI Homes (NASDAQ:<a href='https://seekingalpha.com/symbol/LGIH' title='LGI Homes, Inc.'>LGIH</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"red\">-21%</font>. China Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='China Bat Group, Inc.'>GLG</a>) <font color=\"red\">-9%</font>. IRSA Inversiones y Representaciones (NYSE:<a href='https://seekingalpha.com/symbol/IRS' title='IRSA Inversiones y Representaciones Sociedad Anónima'>IRS</a>) <font color=\"red\">-7%</font>. Banco Macro (NYSE:<a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a>) <font color=\"red\">-7%</font>. Grupo Financiero Galicia (NASDAQ:<a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446183\" data-linked=\"Hexindai leads financial gainers; China Bat Group and Banco Macro among losers\" data-tweet=\"$HX $MDLY $XHR - Hexindai leads financial gainers; China Bat Group and Banco Macro among losers https://seekingalpha.com/news/3446183-hexindai-leads-financial-gainers-china-bat-group-and-banco-macro-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446183-hexindai-leads-financial-gainers-china-bat-group-and-banco-macro-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446176\" data-ts=\"1553705253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446176-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Reebonz Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Limited'>RBZ</a>) <font color=\"green\">+97%</font>. Navios Maritime Containers (NASDAQ:<a href='https://seekingalpha.com/symbol/NMCI' title='Navios Maritime Containers L.P.'>NMCI</a>) <font color=\"green\">+52%</font>. Castor Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRM' title='Castor Maritime Inc.'>CTRM</a>) <font color=\"green\">+39%</font>. Integrated Media Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/IMTE' title='Integrated Media Technology Limited'>IMTE</a>) <font color=\"green\">+31%</font>. CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) <font color=\"green\">+24%</font>. Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>) <font color=\"green\">+24%</font>. Syndax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>) <font color=\"green\">+21%</font>. Shoe Carnival (NASDAQ:<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a>) <font color=\"green\">+21%</font>. Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"green\">+15%</font>. Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>) <font color=\"green\">+15%</font>.</li><li><strong>Losers:  </strong>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"red\">-45%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-30%</font>. DropCar (NASDAQ:<a href='https://seekingalpha.com/symbol/DCAR' title='DropCar, Inc.'>DCAR</a>) <font color=\"red\">-28%</font>. Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"red\">-28%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"red\">-21%</font>. Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"red\">-20%</font>. At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"red\">-20%</font>. CounterPath (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"red\">-19%</font>. CM Seven Star Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/CMSS' title='CM Seven Star Acquisition Corporation'>CMSS</a>) <font color=\"red\">-17%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446176\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RBZ $NMCI $CTRM - Midday Gainers / Losers https://seekingalpha.com/news/3446176-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446176-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446167\" data-ts=\"1553703374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IFNNY\" target=\"_blank\">IFNNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446167-u-s-semis-slide-on-infineon-forecast-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. semis slide on Infineon forecast cut</a></h4><ul><li>The Philadelphia Semiconductor Index <font color=\"red\">drops 1.7%</font> as U.S. chipmakers slide after German peer Infineon (<a href='https://seekingalpha.com/symbol/IFNNY' title='Infineon Technologies AG'>OTCQX:IFNNY</a>) <a href=\"https://www.reuters.com/article/us-infineon-technol-outlook/infineon-cuts-sales-forecast-again-on-weak-china-car-market-idUSKCN1R81IQ\" target=\"_blank\">cuts</a> its 2019 forecast for the second time in two months.</li><li>Infineon now expects revenue of within 2% of $9B, up 5% on the year compared to the previous +9% expected.</li><li>The company attributes the cut to \"slower demand recovery than expected\" with a number of end markets still \"sluggish,\" particularly China's declining auto sales.</li><li>Yesterday, Samsung <a href=\"https://seekingalpha.com/news/3445558-samsung-warns-earnings-due-memory-weakness\" target=\"_blank\">said</a> its Q1 profit would likely miss expectations due to memory weakness.</li><li>Semi movers include Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a> <font color='red'>-2.6%</font>), Microchip (<a href='https://seekingalpha.com/symbol/MCHP' title='Microchip Technology Incorporated'>MCHP</a> <font color='red'>-3.3%</font>), Monolith Power Systems (<a href='https://seekingalpha.com/symbol/MPWR' title='Monolithic Power Systems, Inc.'>MPWR</a> <font color='red'>-3.8%</font>), Analog Devices (<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices, Inc.'>ADI</a> <font color='red'>-2.5%</font>), Texas Instruments (<a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Incorporated'>TXN</a> <font color='red'>-2.1%</font>), and Skyworks Solutions (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='red'>-2.2%</font>).</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3446167\" data-linked=\"U.S. semis slide on Infineon forecast cut\" data-tweet=\"$IFNNY $IFNNY $MU - U.S. semis slide on Infineon forecast cut https://seekingalpha.com/news/3446167-u-s-semis-slide-on-infineon-forecast-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3446167-u-s-semis-slide-on-infineon-forecast-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446163\" data-ts=\"1553702950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRTC\" target=\"_blank\">IRTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446163-irhythm-down-13-on-cautious-research-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IRhythm down 13% on cautious research report</a></h4><ul><li>Thinly traded iRhythm Technologies (<a href='https://seekingalpha.com/symbol/IRTC' title='iRhythm Technologies, Inc.'>IRTC</a> <font color=\"red\">-12.6%</font>) is down on a 5x surge in volume in apparent response to a cautious report from boutique research outfit <a href=\"http://washingtonanalysis.com/\" target=\"_blank\">Washington Analysis</a> who estimates that the company's <a href=\"https://www.irhythmtech.com/patients/why-zio\" target=\"_blank\">Zio XT</a> monitor could face a substantial Medicare reimbursement cut of 45 - 65%, although it may not take effect until the latter half of 2021.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446163\" data-linked=\"IRhythm down 13% on cautious research report\" data-tweet=\"$IRTC - IRhythm down 13% on cautious research report https://seekingalpha.com/news/3446163-irhythm-down-13-on-cautious-research-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3446163-irhythm-down-13-on-cautious-research-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446162\" data-ts=\"1553702763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFIN\" target=\"_blank\">PFIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446162-on-p-and-f-industries-fy18-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on P&amp;F Industries FY18 results</a></h4><div><ul><li>P&amp;F Industries (<a href='https://seekingalpha.com/symbol/PFIN' title='P&F Industries, Inc.'>PFIN</a> <font color=\"green\">+1.5%</font>) reported FY18 revenue growth of 10.2% Y/Y to $65M, with Florida Pneumatic at $50.72M (+9.1% Y/Y) and Hy-Tech $14.27M (+14.2% Y/Y).</li><li>Florida Pneumatic revenue $50.72M, with Retail customers $18.23M (-8.3% Y/Y); Automotive $14.43M (+3.8% Y/Y); Industrial/catalog $6.78M (+27.9% Y/); Aerospace $10.61M (+63.1% Y/Y); and Others $661k (-23.8% Y/Y); Gross margin of 36.6% <font color=\"red\">down by 90 bps</font>.</li><li>Hy-Tech revenue $14.27M (+14.2% Y/Y) with ATP $12.96M (+16.6% Y/Y) and others $1.32M (-5% Y/Y); and gross margin 32.5% <font color=\"green\">up by 330 bps</font>.</li><li>FY Overall gross margin Overall margin <font color=\"red\">declined slightly by 10 bps</font> to 35.7%; and operating margin <font color=\"green\">improved by 220 bps </font>to 2.3%.</li><li>FY EBITDA increased by 69.5% Y/Y to $3.42M and margin <font color=\"green\">improved by 182 bps</font> to 5.3%.</li><li>SG&amp;A expenses were $21.7M up by 3.2% Y/Y.</li><li>Cash provided by operating activities was $2.97M, compared to $4.63M a year ago. Company has a cash balance of $999k, as of December 31, 2018.</li><li>Capital spending was $1.88M for FY18. Capital expenditures currently planned for 2019 are ~$1.74M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446029-p-and-f-industries-reports-fy-results\" target=\"_blank\">P &amp; F Industries reports FY results</a> (March 27)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3446162\" data-linked=\"More on P&amp;F Industries FY18 results\" data-tweet=\"$PFIN - More on P&amp;F Industries FY18 results https://seekingalpha.com/news/3446162-on-p-and-f-industries-fy18-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3446162-on-p-and-f-industries-fy18-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446160\" data-ts=\"1553702567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446160-origin-agritech-leads-consumer-gainers-avon-products-and-iconix-brand-group-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Origin Agritech leads consumer gainers; Avon Products and Iconix Brand Group among losers</a></h4><ul><li><b>Gainers: </b>Origin Agritech (NASDAQ:<a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a>) <font color=\"green\">+8%</font>. Clarus (NASDAQ:<a href='https://seekingalpha.com/symbol/CLAR' title='Clarus Corporation'>CLAR</a>) <font color=\"green\">+6%</font>. UniFirst (NYSE:<a href='https://seekingalpha.com/symbol/UNF' title='UniFirst Corporation'>UNF</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"red\">-19%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-17%</font>. Avon Products (NYSE:<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a>) <font color=\"red\">-12%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"red\">-10%</font>. Truett-Hurst (NASDAQ:<a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446160\" data-linked=\"Origin Agritech leads consumer gainers; Avon Products and Iconix Brand Group among losers\" data-tweet=\"$SEED $CLAR $UNF - Origin Agritech leads consumer gainers; Avon Products and Iconix Brand Group among losers https://seekingalpha.com/news/3446160-origin-agritech-leads-consumer-gainers-avon-products-and-iconix-brand-group-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446160-origin-agritech-leads-consumer-gainers-avon-products-and-iconix-brand-group-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446152\" data-ts=\"1553701974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNFT\" target=\"_blank\">GNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446152-genfit-opens-22-in-u-s-debut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genfit opens at $22 in U.S. debut</a></h4><ul><li>IPO Genfit (<a href='https://seekingalpha.com/symbol/GNFT' title='GENFIT S.A. ADS'>GNFT</a> <font color=\"green\">+9.4%</font>) opened today at $22 per ADS, about 10% above its <a href=\"https://seekingalpha.com/pr/17456194-genfit-genfit-announces-pricing-global-offering-approval-list-nasdaq-global-select-market\" target=\"_blank\">offering price</a> of $20.32.</li><li>Lead candidate is elafibranor, in Phase 3 development for NASH and Phase 2 development for primary biliary cholangitis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446152\" data-linked=\"Genfit opens at $22 in U.S. debut\" data-tweet=\"$GNFT $GNFTF - Genfit opens at $22 in U.S. debut https://seekingalpha.com/news/3446152-genfit-opens-22-in-u-s-debut?source=tweet\" data-url=\"https://seekingalpha.com/news/3446152-genfit-opens-22-in-u-s-debut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446150\" data-ts=\"1553700944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446150-pets-home-rallies-after-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pets at Home rallies after Citi upgrade</a></h4><ul> <li>Pets at Home Group (<a href='https://seekingalpha.com/symbol/PAHGF' title='Pets at Home Group Plc'>OTC:PAHGF</a>, <a href='https://seekingalpha.com/symbol/PHGPY' title='Pets at Home Group PLC ADR'>OTC:PHGPY</a>) <font color=\"green\">jumps 2.4%</font> in London after Citigroup upgrades the pet supplies/services retailer to a Buy rating.</li> <li>Citi cites confidence in the turnaround plan being instituted by Pets at Home management.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3446150\" data-linked=\"Pets at Home rallies after Citi upgrade\" data-tweet=\"$PAHGF $PHGPY - Pets at Home rallies after Citi upgrade https://seekingalpha.com/news/3446150-pets-home-rallies-after-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3446150-pets-home-rallies-after-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446143\" data-ts=\"1553699478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACFN\" target=\"_blank\">ACFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446143-on-acorn-energys-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Acorn Energy&#39;s Q4 results</a></h4><ul><li>Acorn Energy (<a href='https://seekingalpha.com/symbol/ACFN' title='Acorn Energy, Inc.'>OTC:ACFN</a>) reported Q4 revenue growth of 17% Y/Y to $1.31M, with Monitoring revenue at $722k (+20% Y/Y) and Hardware revenue at $589k (+12% Y/Y).</li><li>Q4 Gross margin<font color=\"green\"> improved by 751 bps</font> to 61.8%.</li><li>Q4 operating loss reduced to $234k, from $536k a year ago.</li><li>Operating expenses decreased by 8.9% Y/Y to $1.04M, with R&amp;D at $143k (+11.7% Y/Y) and G&amp;A at $901k (-11.5% Y/Y).</li><li>Company had consolidated cash and cash equivalents of $973k, as of December 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446084-acorn-energy-reports-q4-results\" target=\"_blank\">Acorn Energy reports Q4 results</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446143\" data-linked=\"More on Acorn Energy&#39;s Q4 results\" data-tweet=\"$ACFN - More on Acorn Energy&#39;s Q4 results https://seekingalpha.com/news/3446143-on-acorn-energys-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3446143-on-acorn-energys-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446142\" data-ts=\"1553699326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446142-fossil-spikes-on-takeover-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil spikes on takeover chatter</a></h4><ul> <li>Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil Group, Inc.'>FOSL</a> <font color='green'>+2.5%</font>) spikes on what traders are attributing to takeover chatter.</li> <li>There aren't any confirmed reports that the company is in talks with anyone.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3446142\" data-linked=\"Fossil spikes on takeover chatter\" data-tweet=\"$FOSL - Fossil spikes on takeover chatter https://seekingalpha.com/news/3446142-fossil-spikes-on-takeover-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3446142-fossil-spikes-on-takeover-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446141\" data-ts=\"1553699322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TELL\" target=\"_blank\">TELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446141-tellurian-eyes-fid-on-louisiana-driftwood-lng-project-in-h1-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tellurian eyes FID on Louisiana Driftwood LNG project in H1 2019</a></h4><ul><li>Tellurian (<a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='green'>+4.2%</font>) plans to <a href=\"https://www.reuters.com/article/us-usa-tellurian-lng-interview/tellurian-to-decide-on-louisiana-driftwood-lng-project-in-first-half-of-2019-idUSKCN1R72T2\" target=\"_blank\">make a final investment decision</a> on its proposed $30B Driftwood liquefied natural gas export project in Louisiana in H1 2019, CEO Meg Gentle says.</li><li>TELL expects to move forward with the first phase of the 27.6M mt/year, or ~4B cf/day, project with roughly a half-dozen customers, which should allow the company to produce first LNG in 2023 and complete the project in 2026, Gentle says.</li><li>Driftwood is one of a dozen U.S. LNG export terminals under development that expect to make a final investment decision in 2019, which together would produce 146M mt/year of LNG; Gentle thinks not all of the proposed projects will go forward, and says the U.S. needs 100M mt/year of new export projects to meet growing use of the fuel.</li><li>The CEO says she sees \"some momentum\" towards an \"amicable conclusion\" to the U.S.-China trade dispute, adding that whenever the rift is over, TELL and Chinese buyers \"stand ready to do transactions.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3446141\" data-linked=\"Tellurian eyes FID on Louisiana Driftwood LNG project in H1 2019\" data-tweet=\"$TELL - Tellurian eyes FID on Louisiana Driftwood LNG project in H1 2019 https://seekingalpha.com/news/3446141-tellurian-eyes-fid-on-louisiana-driftwood-lng-project-in-h1-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3446141-tellurian-eyes-fid-on-louisiana-driftwood-lng-project-in-h1-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446136\" data-ts=\"1553698964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446136-cormedix-and-wellcare-health-plans-among-healthcare-gainers-moleculin-biotech-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix and WellCare Health Plans among healthcare gainers; Moleculin Biotech leads the losers</a></h4><ul><li><b>Gainers: </b>Syndax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>) <font color=\"green\">+20%</font>. CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) <font color=\"green\">+13%</font>. IMAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IMAC' title='IMAC Holdings, Inc.'>IMAC</a>) <font color=\"green\">+13%</font>. India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+10%</font>. WellCare Health Plans (NYSE:<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"red\">-28%</font>. Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"red\">-17%</font>. ImmuCell (NASDAQ:<a href='https://seekingalpha.com/symbol/ICCC' title='ImmuCell Corporation'>ICCC</a>) <font color=\"red\">-16%</font>. iRhythm Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/IRTC' title='iRhythm Technologies, Inc.'>IRTC</a>) <font color=\"red\">-15%</font>. Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446136\" data-linked=\"CorMedix and WellCare Health Plans among healthcare gainers; Moleculin Biotech leads the losers\" data-tweet=\"$SNDX $CRMD $IMAC - CorMedix and WellCare Health Plans among healthcare gainers; Moleculin Biotech leads the losers https://seekingalpha.com/news/3446136-cormedix-and-wellcare-health-plans-among-healthcare-gainers-moleculin-biotech-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446136-cormedix-and-wellcare-health-plans-among-healthcare-gainers-moleculin-biotech-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446129\" data-ts=\"1553698842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELOX\" target=\"_blank\">ELOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446129-eloxx-pharma-up-2-on-encouraging-elxminus-02-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eloxx Pharma up 2% on encouraging ELX-02 data</a></h4><ul><li>Thinly traded micro cap Eloxx Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a> <font color=\"green\">+1.7%</font>) is up on below-average volume on the heels of encouraging <a href=\"https://seekingalpha.com/pr/17456808-eloxx-pharmaceuticals-presents-positive-new-data-lead-investigational-drug-elxminus-02\" target=\"_blank\">preclinical data</a> on lead candidate ELX-02 in cystic fibrosis &#40;CF&#41;. The results were presented at the ECFS Basic Science Conference in Croatia.</li><li>The company says small molecule ELX-02 significantly increased CFTR protein expression in organoids derived from CF patients (CF is caused by mutations in the CFTR gene which causes the deficiency/absence of the CFTR protein).</li><li>Eloxx plans to launch a Phase 2 study in the U.S. and Europe this year in CF patients carrying at least one G542X mutation, adding that it expects to report topline results this year as well.</li><li><a href=\"https://www.eloxxpharma.com/pipeline/\" target=\"_blank\">ELX-02</a> is a eukaryotic ribosomal selective glycoside, a compound that modulates the ribosome, a part of the cell that plays a major role in protein production. It is designed to increase the read-through activity in patients with nonsense mutations, enabling the production of enough full-length protein to restore biochemical activity.</li><li>CF-related tickers: Proteostasis Therapeutics (<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a> <font color=\"red\">-7.9%</font>); Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"red\">-0.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446129\" data-linked=\"Eloxx Pharma up 2% on encouraging ELX-02 data\" data-tweet=\"$ELOX $PTI $VRTX - Eloxx Pharma up 2% on encouraging ELX-02 data https://seekingalpha.com/news/3446129-eloxx-pharma-up-2-on-encouraging-elxminus-02-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3446129-eloxx-pharma-up-2-on-encouraging-elxminus-02-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446120\" data-ts=\"1553697257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRIO\" target=\"_blank\">DRIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446120-dariohealth-teams-up-glytec-in-diabetes-management\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DarioHealth teams up with Glytec in diabetes management</a></h4><ul><li>DarioHealth (<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color=\"green\">+5.4%</font>) inks a joint marketing <a href=\"https://seekingalpha.com/pr/17456487-dariohealth-partners-glytec-outpatient-diabetes-management\" target=\"_blank\">agreement</a> with <a href=\"https://www.glytecsystems.com/\" target=\"_blank\">Glytec </a>aimed at virtual insulin titration for outpatient diabetics.</li><li>Patients using DRIO's Blood Glucose Monitoring System will receive personalized insulin dose recommendations via Glytec's cloud-based <a href=\"https://www.glytecsystems.com/Solutions.html\" target=\"_blank\">Glucommander </a>Outpatient software-as-a-medical device based on information sent from the smart glucose meter (together with other clinical data).</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446120\" data-linked=\"DarioHealth teams up with Glytec in diabetes management\" data-tweet=\"$DRIO - DarioHealth teams up with Glytec in diabetes management https://seekingalpha.com/news/3446120-dariohealth-teams-up-glytec-in-diabetes-management?source=tweet\" data-url=\"https://seekingalpha.com/news/3446120-dariohealth-teams-up-glytec-in-diabetes-management\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446125\" data-ts=\"1553697091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TUR\" target=\"_blank\">TUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446125-investors-dump-turkish-stocks-bonds-amid-currency-crunch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors dump Turkish stocks, bonds amid currency crunch</a></h4><ul><li>The cost of borrowing Turkish liras overnight<a href=\"https://www.bloomberg.com/news/articles/2019-03-27/foreign-investors-are-trapped-in-turkey-days-before-elections\" target=\"_blank\"> soared </a>past 1,000% on Wednesday as local banks are being pressured to not provide liquidity to foreign fund managers seeking to bet against the lira.</li><li>As a result, investors sold Turkish bonds and stocks amid the currency crunch that was intended to prevent the lira from declining days before local elections this weekend.</li><li>The yield on two-year Turkish bonds surged above 20% and stocks fell the most since August.</li><li>The lira <font color=\"red\">sinks 1.5%</font> against the U.S. dollar.</li><li>iShares MSCI Turkey ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/TUR' title='iShares MSCI Turkey ETF'>TUR</a>)<font color=\"red\"> slumps 7.1%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445964-turkish-banks-continue-withhold-lira-liquidity\" target=\"_blank\">Turkish banks continue to withhold lira liquidity</a> (March 27)</li><li>Related Stocks: <a href='https://seekingalpha.com/symbol/TKC' title='Turkcell Iletisim Hizmetleri A.S.'>TKC</a>, <a href='https://seekingalpha.com/symbol/COCAL' title='Coca Cola Icecek Sanayi As ADR'>OTC:COCAL</a>, <a href='https://seekingalpha.com/symbol/TKGBF' title='Turkiye Garanti Bankasi A.S.'>OTCQX:TKGBF</a>, <a href='https://seekingalpha.com/symbol/AKBTY' title='Akbank T.A.S.'>OTCQX:AKBTY</a>, <a href='https://seekingalpha.com/symbol/TKGBY' title='Turkiye Garanti Bankasi A.S.'>OTCQX:TKGBY</a>, <a href='https://seekingalpha.com/symbol/KHOLY' title='Koç Holding Anonim Sirketi'>OTCPK:KHOLY</a>, <a href='https://seekingalpha.com/symbol/TYIBF' title='Türkiye Is Bankasi A.S.'>OTC:TYIBF</a>, <a href='https://seekingalpha.com/symbol/FOVSY' title='Ford Otomotiv Sanayi A.S.'>OTCPK:FOVSY</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3446125\" data-linked=\"Investors dump Turkish stocks, bonds amid currency crunch\" data-tweet=\"$TUR $TKC $COCAL - Investors dump Turkish stocks, bonds amid currency crunch https://seekingalpha.com/news/3446125-investors-dump-turkish-stocks-bonds-amid-currency-crunch?source=tweet\" data-url=\"https://seekingalpha.com/news/3446125-investors-dump-turkish-stocks-bonds-amid-currency-crunch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446122\" data-ts=\"1553696745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICON\" target=\"_blank\">ICON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446122-iconixminus-12-after-soft-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iconix -12% after soft quarter</a></h4><ul> <li>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) is <font color=\"red\">down 12.2%</font> after the company's <a href=\"https://seekingalpha.com/pr/17456670-iconix-reports-financial-results-fourth-quarter-and-full-year-2018\" target=\"_blank\">Q4</a> report and guidance update disappoints investors.</li> <li>Revenue fell 16% Y/Y in Q4 due in part to the bankruptcy of Sears. The women's business fell off 56% during the quarter.</li> <li>Looking ahead, Iconix expects full-year revenue of $145M to $160M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446049-iconix-brand-eps-9_75\" target=\"_blank\">Iconix Brand EPS of -$9.75</a> (March 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446122\" data-linked=\"Iconix -12% after soft quarter\" data-tweet=\"$ICON - Iconix -12% after soft quarter https://seekingalpha.com/news/3446122-iconixminus-12-after-soft-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3446122-iconixminus-12-after-soft-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446115\" data-ts=\"1553696323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446115-moleculin-down-29-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin down 29% after pricing equity offering</a></h4><ul><li>Thinly traded nano cap Moleculin Biotech (<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color=\"red\">-28.7%</font>) slumps on more than an 11x surge in volume in reaction to its <a href=\"https://seekingalpha.com/pr/17456864-moleculin-announces-pricing-underwritten-public-offering\" target=\"_blank\">public offering</a> of 5.25M units at $1.00 per unit.</li><li>Each unit consists of one common share and 1/2 of a five-year warrant to purchase one common share at $1.10.</li><li>Closing date is March 29.</li><li>Yesterday's close was $1.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446115\" data-linked=\"Moleculin down 29% after pricing equity offering\" data-tweet=\"$MBRX - Moleculin down 29% after pricing equity offering https://seekingalpha.com/news/3446115-moleculin-down-29-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3446115-moleculin-down-29-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446109\" data-ts=\"1553695927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446109-salesforceminus-1_7-on-suit-from-trafficking-victims\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salesforce -1.7% on suit from trafficking victims</a></h4><ul><li>Salesforce (NYSE:<a href='https://seekingalpha.com/symbol/CRM' title='salesforce.com, inc.'>CRM</a>)<font color=\"red\"> drops 1.7% </font>on news that 50 women are <a href=\"https://www.cnbc.com/2019/03/27/lawsuit-claims-salesforce-worked-with-sex-trafficking-site-backpage.html\" target=\"_blank\">suing the company</a> for selling custom tools to sex trafficking website Backpage.</li><li>The anonymous women are identified as victims of trafficking, rape, and abuse facilitated through Backpage.</li><li>The suit says that Salesforce designed and implemented a \"heavily customized\" enterprise database that was the backbone of the site's growth. The setup allowed Backpage to attract new \"users\" including \"pimps, johns, and traffickers\" on three continents.</li><li>Salesforce says it doesn't comment on pending litigation but is \"deeply committed to the ethical and humane use of our products and take these allegations seriously.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3446109\" data-linked=\"Salesforce -1.7% on suit from trafficking victims\" data-tweet=\"$CRM - Salesforce -1.7% on suit from trafficking victims https://seekingalpha.com/news/3446109-salesforceminus-1_7-on-suit-from-trafficking-victims?source=tweet\" data-url=\"https://seekingalpha.com/news/3446109-salesforceminus-1_7-on-suit-from-trafficking-victims\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446105\" data-ts=\"1553695658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POLA\" target=\"_blank\">POLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446105-on-polar-powers-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Polar Power&#39;s Q4 results</a></h4><ul><li>Polar Power (<a href='https://seekingalpha.com/symbol/POLA' title='Polar Power, Inc.'>POLA</a> <font color=\"red\">-0.3%</font>) reported Q4 revenue growth of 108.3% Y/Y to $8.29M, reflecting increase in sales of DC power systems to Tier-1 wireless carrier customers, along with increase in international and government sales.</li><li>Q4 Gross margin <font color=\"red\">declined by 296 bps</font> to 28.4%; and operating margin <font color=\"green\">recovered by 991 bps </font>to -2.5%.</li><li>Q4 Operating expenses increased by 47.2% Y/Y to $2.56M, with Sales &amp; marketing $611.3k (+24.5% Y/Y), R&amp;D $535.83k (+38.4% Y/Y), and G&amp;A $1.42M (+63.3% Y/Y).</li><li>Total Backlog was at $16M as of December 31, 2018.</li><li>Net cash used in operating activities YTD was $7.85M, compared to $1.59M a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445876-polar-power-misses-0_03-beats-revenue\" target=\"_blank\">Polar Power misses by $0.03, beats on revenue</a> (March 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446105\" data-linked=\"More on Polar Power&#39;s Q4 results\" data-tweet=\"$POLA - More on Polar Power&#39;s Q4 results https://seekingalpha.com/news/3446105-on-polar-powers-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3446105-on-polar-powers-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446106\" data-ts=\"1553695646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OIS\" target=\"_blank\">OIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446106-oil-statesplus-6-following-raymond-james-upgrade-to-strong-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil States +6% following Raymond James upgrade to Strong Buy</a></h4><ul><li>Oil States International (<a href='https://seekingalpha.com/symbol/OIS' title='Oil States International, Inc.'>OIS</a> <font color=\"green\">+6.5%</font>) jumps in early trading after Raymond James <a href=\"https://thefly.com/thestreet/realmoney/index.php/OISid2884987/OIS-Oil-States-upgraded-to-Strong-Buy-on-valuation-at-Raymond-James\" target=\"_blank\">upgrades shares to Strong Buy</a> from Outperform with a $27 price target, raised from $26, citing valuation.</li><li>Ray Jay's Marshall Adkins says OIS shares have lagged the oilfield services sector recovery in 2019 and had one of the largest pullbacks over the past several months.</li><li>The analyst sees meaningful upside to 2019 and 2019 consensus estimates and says OIS trades at a \"historically low\" 6.85x 2020 EBITDA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446106\" data-linked=\"Oil States +6% following Raymond James upgrade to Strong Buy\" data-tweet=\"$OIS - Oil States +6% following Raymond James upgrade to Strong Buy https://seekingalpha.com/news/3446106-oil-statesplus-6-following-raymond-james-upgrade-to-strong-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3446106-oil-statesplus-6-following-raymond-james-upgrade-to-strong-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446103\" data-ts=\"1553695478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTNR\" target=\"_blank\">PTNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446103-partner-communicationsplus-5_2-q4-swings-to-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Partner Communications +5.2% as Q4 swings to profit</a></h4><ul>   <li>Partner Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a>) is <font color=\"green\">up 5.2%</font> after reporting <a href=\"https://seekingalpha.com/news/3445945-partner-communication-reports-q4-results\" target=\"_blank\">Q4 results</a> that showed broad declines but were less disappointing than Israeli observers expected.</li>    <li>Shares had <font color=\"red\">pulled back 23%</font> this year before the quarter's news.</li>    <li>Revenues overall dropped just 2% to 814M shekels (about $217M), and service revenues dropped just 1% to 625M shekels.</li>    <li>Meanwhile costs fell further (opex down 3% to 502M shekels), leading to a swing to profit of 19M shekels (about $5M).</li>    <li>EBITDA rose by 9%, meanwhile, to 172M shekels, and EBITDA margin rose to 21% from 19%.</li>    <li>Cellular subscribers fell about 1% to 2.65M; ARPU dropped 3% to 57 shekels (about $15). TV subscribers increased by 79,000 to hit 122,000.</li>    <li><a href=\"https://seekingalpha.com/pr/17456233-partner-communications-reports-fourth-quarter-annual-2018-results-1\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3446103\" data-linked=\"Partner Communications +5.2% as Q4 swings to profit\" data-tweet=\"$PTNR - Partner Communications +5.2% as Q4 swings to profit https://seekingalpha.com/news/3446103-partner-communicationsplus-5_2-q4-swings-to-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3446103-partner-communicationsplus-5_2-q4-swings-to-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446102\" data-ts=\"1553695450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446102-nio-and-kandi-take-back-ground\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nio and Kandi take back ground</a></h4><ul> <li>Nio (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) is <font color=\"green\">up 3.5%</font> and Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) is <font color=\"green\">4.4% higher</font> as investors take a second look at yesterday's report on a cut by China on EV subsidies.</li> <li>\"Beijing\u2019s latest measures should reassure investors about the industry\u2019s long-term outlook, even if slashed subsidies deflate some companies' tires for a little while,\" <a href=\"https://www.wsj.com/articles/beijing-gives-electric-vehicle-makers-a-long-term-power-surge-11553681202\" target=\"_blank\">notes</a> The Wall Street Journal's Jacky Wong.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3445740-china-scales-back-ev-subsidies\" target=\"_blank\">China scales back EV subsidies</a> (March 26)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446102\" data-linked=\"Nio and Kandi take back ground\" data-tweet=\"$NIO $KNDI - Nio and Kandi take back ground https://seekingalpha.com/news/3446102-nio-and-kandi-take-back-ground?source=tweet\" data-url=\"https://seekingalpha.com/news/3446102-nio-and-kandi-take-back-ground\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446095\" data-ts=\"1553694633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMCI\" target=\"_blank\">NMCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446095-navios-maritime-containers-pops-after-jpmorgan-call-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navios Maritime Containers pops after JPMorgan call-out</a></h4><ul> <li>Navios Maritime Containers (<a href='https://seekingalpha.com/symbol/NMCI' title='Navios Maritime Containers L.P.'>NMCI</a> <font color='green'>+24.2%</font>) gains after JPMorgan initiates coverage on the containership company with an Overweight rating.</li> <li>JP assigns a price target of $9 to NMCI to rep +350% upside potential on shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3446095\" data-linked=\"Navios Maritime Containers pops after JPMorgan call-out\" data-tweet=\"$NMCI - Navios Maritime Containers pops after JPMorgan call-out https://seekingalpha.com/news/3446095-navios-maritime-containers-pops-after-jpmorgan-call-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3446095-navios-maritime-containers-pops-after-jpmorgan-call-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446079\" data-ts=\"1553693041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIPT\" target=\"_blank\">AIPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446079-precision-therapeutics-down-9-premarket-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Precision Therapeutics down 9% premarket on equity offering</a></h4><ul><li>Thinly traded nano cap Precision Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIPT' title='Precision Therapeutics Inc.'>AIPT</a>) slips <font color=\"red\">9% </font>premarket on modestly higher volume in reaction to its <a href=\"https://seekingalpha.com/pr/17456733-precision-therapeutics-inc-announces-pricing-public-offering-1_2-million-units\" target=\"_blank\">public offering</a> of 1.5M units at $0.80 per unit on a \"best efforts\" basis.</li><li>Each unit consists of one common share and one five-year warrant to purchase 1/2 of a common share at $1.00.</li><li>Closing date is March 29.</li><li>Yesterday's close was $0.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446079\" data-linked=\"Precision Therapeutics down 9% premarket on equity offering\" data-tweet=\"$AIPT $POAI - Precision Therapeutics down 9% premarket on equity offering https://seekingalpha.com/news/3446079-precision-therapeutics-down-9-premarket-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3446079-precision-therapeutics-down-9-premarket-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446078\" data-ts=\"1553693028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VXRT\" target=\"_blank\">VXRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446078-vaxartplus-8-on-completing-dosing-in-norovirus-vaccine-phase-1b-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaxart +8% on completing dosing in norovirus vaccine phase 1b trial</a></h4><ul> <li>Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) <a href=\"https://seekingalpha.com/pr/17456542-vaxart-completes-dosing-lead-cohort-bivalent-norovirus-vaccine-phase-1b-clinical-trial\" target=\"_blank\">completes</a> dosing of the lead-in       cohort in the Phase 1b bivalent norovirus vaccine clinical trial with       its oral norovirus GII.4 vaccine.</li>     <li>The trial consists of two parts, a lead-in phase which has now been completed, and a placebo-controlled phase which is expected to start in       April, subject to final review by the FDA.</li><li>Both portions of the trial       are designed to evaluate safety and immunogenicity.</li><li>The Company expects       to receive topline data in H2.</li><li>Shares are up <font color=\"green\">8%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3446078\" data-linked=\"Vaxart +8% on completing dosing in norovirus vaccine phase 1b trial\" data-tweet=\"$VXRT - Vaxart +8% on completing dosing in norovirus vaccine phase 1b trial https://seekingalpha.com/news/3446078-vaxartplus-8-on-completing-dosing-in-norovirus-vaccine-phase-1b-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3446078-vaxartplus-8-on-completing-dosing-in-norovirus-vaccine-phase-1b-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446076\" data-ts=\"1553692864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446076-riot-amrs-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RIOT, AMRS among premarket gainers</a></h4><ul><li>Reebonz Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Limited'>RBZ</a>) <font color=\"green\">+89%</font>.</li><li>Castor Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRM' title='Castor Maritime Inc.'>CTRM</a>) <font color=\"green\">+40%</font>.</li><li>China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"green\">+30%</font>.</li><li>Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>) <font color=\"green\">+22%</font>.</li><li>Shoe Carnival (NASDAQ:<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/news/3445864-shoe-carnival-beats-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+17%</font> a cannabinoid-based non-FDA approved <a href=\"https://seekingalpha.com/pr/17456176-igc-provides-corporate-updates\" target=\"_blank\">product</a> designed to assist in helping improve the lives of patients suffering from Alzheimer\u2019s disease, will be available for purchase in select dispensaries in San Juan, Puerto Rico.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+14% </font>as FDA <a href=\"https://seekingalpha.com/news/3446015-axsomes-axsminus-05-breakthrough-therapy-mdd-shares-14-percent-premarket\" target=\"_blank\">granted</a> Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder.</li><li>Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"green\">+12%</font>.</li><li>WellCare Health Plans (NYSE:<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a>) <font color=\"green\">+10%</font> on being <a href=\"https://seekingalpha.com/news/3445972-centene-acquire-wellcare-17_3b\" target=\"_blank\">acquired</a> by Centene.</li><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3446052-aytu-bio-12-percent-premarket-positive-post-market-natesto-data\" target=\"_blank\">positive</a> post-market Natesto data.</li><li>Performance Shipping (NASDAQ:<a href='https://seekingalpha.com/symbol/DCIX' title='Performance Shipping Inc.'>DCIX</a>) <font color=\"green\">+5%</font>.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+6%</font>.</li><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+6%</font>.</li><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3445985-viking-therapeutics-7-percent-premarket-positive-vk2809-data\" target=\"_blank\">positive</a> VK2809 data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446076\" data-linked=\"RIOT, AMRS among premarket gainers\" data-tweet=\"$RBZ $CTRM $SXTC - RIOT, AMRS among premarket gainers https://seekingalpha.com/news/3446076-riot-amrs-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446076-riot-amrs-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446067\" data-ts=\"1553692728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPCN\" target=\"_blank\">LPCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446067-lipocine-to-refile-tlando-nda-next-quarter-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lipocine to refile Tlando NDA next quarter, shares up 4% premarket</a></h4><ul> <li>Checking off one of the boxes cited in the <a href=\"https://seekingalpha.com/news/3354426-fda-rejects-lipocines-application-trt-med-tlando-shares-38-percent-premarket\" target=\"_blank\">CRL </a>it received in May 2018, Lipocine (NASDAQ:<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a>) <a href=\"https://seekingalpha.com/pr/17456532-lipocine-announces-abpm-labeling-study-results-consistent-recently-approved-testosterone\" target=\"_blank\">announces</a> topline results from a study evaluating TLANDO's effects on blood pressure.</li>                    <li>Of the subjects (n=25) with baseline 24-hour average systolic blood pressure &#40;SBP&#41; greater than 140 mm Hg, 32% were less than or equal to 140 mm Hg at the end of study.</li> <li>In subjects (n=93) with baseline 24-hour average SBP of less than or equal to 140 mm Hg, 9.7% were greater than 140 mm Hg at the end of study.</li> <li>TLANDO was generally well-tolerated with no new safety signals observed.</li> <li>The company plans to resubmit the application next quarter.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446067\" data-linked=\"Lipocine to refile Tlando NDA next quarter, shares up 4% premarket\" data-tweet=\"$LPCN - Lipocine to refile Tlando NDA next quarter, shares up 4% premarket https://seekingalpha.com/news/3446067-lipocine-to-refile-tlando-nda-next-quarter-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3446067-lipocine-to-refile-tlando-nda-next-quarter-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446071\" data-ts=\"1553692634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446071-cnc-titn-and-home-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNC, TITN and HOME among premarket losers</a></h4><ul><li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"red\">-25%</font> on <a href=\"https://seekingalpha.com/news/3445918-moleculin-biotech-readies-equity-offering-shares-21-percent\" target=\"_blank\">announcing</a> equity offering.</li><li>DropCar (NASDAQ:<a href='https://seekingalpha.com/symbol/DCAR' title='DropCar, Inc.'>DCAR</a>) <font color=\"red\">-24%</font>.</li><li>Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"red\">-20%</font> on updated <a href=\"https://seekingalpha.com/news/3446030-fibrocell-18-percent-premarket-updated-fcxminus-007-data\" target=\"_blank\">FCX-007</a> data.</li><li>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3445951-inpixon-reports-q4-results\" target=\"_blank\">Q4 results</a>.</li><li>At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3445968-home-group-misses-0_01-beats-revenue\" target=\"_blank\">Q4 results</a>.</li><li>CounterPath (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"red\">-13%</font>.</li><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3445972-centene-acquire-wellcare-17_3b\" target=\"_blank\">acquiring</a> WellCare for $17.3B.</li><li>CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3445891-cbl-suspend-dividends-payable-q3-q4\" target=\"_blank\">suspending</a> Q3 and Q4 dividend.</li><li>Titan Machinery (NASDAQ:<a href='https://seekingalpha.com/symbol/TITN' title='Titan Machinery Inc.'>TITN</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3445971-titan-machinery-misses-0_05-beats-revenue\" target=\"_blank\">Q4 results</a>.</li><li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a href='https://seekingalpha.com/symbol/TKC' title='Turkcell Iletisim Hizmetleri A.S.'>TKC</a>) <font color=\"red\">-9%</font>.</li><li>VEON (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd.'>VEON</a>) <font color=\"red\">-7%</font> after Telenor <a href=\"https://seekingalpha.com/news/3445882-veon-minus-1_9-percent-announces-telenor-offering-85m-shares\" target=\"_blank\">offering</a> 85M shares.</li><li>HyreCar (NASDAQ:<a href='https://seekingalpha.com/symbol/HYRE' title='HyreCar Inc.'>HYRE</a>) <font color=\"red\">-5%</font>.</li><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446071\" data-linked=\"CNC, TITN and HOME among premarket losers\" data-tweet=\"$MBRX $DCAR $FCSC - CNC, TITN and HOME among premarket losers https://seekingalpha.com/news/3446071-cnc-titn-and-home-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3446071-cnc-titn-and-home-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446069\" data-ts=\"1553692492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446069-baird-expects-chipotle-rally-to-extend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird expects Chipotle rally to extend</a></h4><ul> <li>Baird hikes its price target on Outperform-rated Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) to $760 from $650.</li> <li>The firm expects Chipotle's operating improvements to continue to pay off in 2019 and feed earnings reports as they roll in.</li> <li>\"Although CMG may be due for a short-term breather following the robust year-to-date return (+60% vs. S&amp;P 500 +12%), we continue to see a path for the shares to outperform over the next 12 months based on potential for the company to show strong operating momentum throughout 2019, which in our opinion, should help to support investor confidence in sizable long-term earnings power scenarios and keep the multiples on near-term estimates elevated,\" reads the Baird note in part.</li> <li>The average PT on Wall Street is $556.67 across the 11 Buy-equivalent ratings, 15 Hold-equivalent ratings and 7 Sell-equivalent ratings on the books.</li>  <li>Shares of CMG are <font color=\"green\">up 0.31%</font> premarket to $688.82 and are 59% higher in 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446069\" data-linked=\"Baird expects Chipotle rally to extend\" data-tweet=\"$CMG - Baird expects Chipotle rally to extend https://seekingalpha.com/news/3446069-baird-expects-chipotle-rally-to-extend?source=tweet\" data-url=\"https://seekingalpha.com/news/3446069-baird-expects-chipotle-rally-to-extend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446066\" data-ts=\"1553691990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446066-google-will-go-light-on-ad-changes-stifel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Google will go light on ad changes - Stifel</a></h4><ul><li>Stifel analyst John Egber thinks Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a>,<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a>) will want to improve Chrome data privacy protections in some way, but the approach might be less \"heavy-handed\" than Apple's considering how much revenue Google gets from ads. </li><li>Egbert, in a note out late yesterday: \"If Google were to decimate its adtech competitors\u2019 business models overnight by imposing changes as restrictive as Apple\u2019s ITP, the company could face even more antitrust scrutiny than it is already dealing with.\"</li><li>BMO analyst Dan Salmon warns investors not \"jump to assumptions\" on any potential changes and expects Google to provide details ahead of its May 14 market event.</li><li>The notes could send ad-tech firm shares into the green today with potential movers including Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>), LiveRamp (NYSE:<a href='https://seekingalpha.com/symbol/RAMP' title='LiveRamp Holdings, Inc.'>RAMP</a>), The Trade Desk (NASDAQ:<a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk, Inc.'>TTD</a>), and Rubicon Project (NYSE:<a href='https://seekingalpha.com/symbol/RUBI' title='the Rubicon Project, Inc.'>RUBI</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445411-ad-tech-firms-drop-google-mulls-chrome-ad-changes\" target=\"_blank\">Ad-tech firms drop as Google mulls Chrome ad changes</a> (March 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446066\" data-linked=\"Google will go light on ad changes - Stifel\" data-tweet=\"$GOOG $GOOGL $CRTO - Google will go light on ad changes - Stifel https://seekingalpha.com/news/3446066-google-will-go-light-on-ad-changes-stifel?source=tweet\" data-url=\"https://seekingalpha.com/news/3446066-google-will-go-light-on-ad-changes-stifel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446059\" data-ts=\"1553691482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446059-cronos-groupminus-4-after-3-post-earnings-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cronos Group -4% after 3 post-earnings downgrades</a></h4><ul><li>Underwhelmed by the company's Q4 results, or perhaps just cashing in chips after a nice run higher for the stock, two bulls downgrade Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a>):</li><li>PI Financial's Jason Zandberg cuts to Neutral from Buy. Cormark's Jesse Pytlak downgrades to Market Perform from Speculative Buy.</li><li>And one middle-of-the-roaders turn bear:</li><li>Canaccord's Matt Bottomley downgrades to Sell from Hold, noting a perky valuation and a \"soft start\" to Canada's adult-use market.</li><li>There's one bull boosting his target ... CIBC's John Zamparo acknowledges the \"underwhelming\" Q4, but isn't too concerned, instead noting \"numerous positive catalysts\" - U.S. banking reform, possible legalization in Israel, and strategic M&amp;A among them. He lifts his PT to C$30 from C$22.</li><li>Shares are <font color=\"red\">down 4.15%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446059\" data-linked=\"Cronos Group -4% after 3 post-earnings downgrades\" data-tweet=\"$CRON - Cronos Group -4% after 3 post-earnings downgrades https://seekingalpha.com/news/3446059-cronos-groupminus-4-after-3-post-earnings-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3446059-cronos-groupminus-4-after-3-post-earnings-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446052\" data-ts=\"1553690853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446052-aytu-bio-up-12-premarket-positive-post-market-natesto-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio up 12% premarket positive post-market Natesto data</a></h4><ul><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) is up <font color=\"green\">12%</font> premarket on light volume on the heels of <a href=\"https://seekingalpha.com/pr/17456607-aytu-bioscience-provides-study-update-spermatogenesis-study-natesto-r-fda-approved-nasally\" target=\"_blank\">updated results</a> from a post-market Phase 4 study assessing the effects of <a href=\"https://natesto.com/\" target=\"_blank\">Natesto</a>, a nasally administered testosterone replacement therapy, on sperm production. The data were presented at the Endocrine Society Annual Meeting in New Orleans.</li><li>15 subjects completed the six-month treatment period. Serum testosterone levels returned to normal while all semen measures, including sperm concentration, motility and total motile sperm count remained statistically unchanged through three months and six months of therapy.</li><li>All participants (56 enrolled to date) should complete six months of treatment this summer. Final results will be released shortly thereafter.</li><li>Traditional testosterone replacement therapy &#40;TRT&#41; has been associated with decreased gonadotropin levels, diminished sperm production/function and decreased production of endogenous testosterone.</li><li>The FDA approved Natesto in May 2014.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446052\" data-linked=\"Aytu Bio up 12% premarket positive post-market Natesto data\" data-tweet=\"$AYTU - Aytu Bio up 12% premarket positive post-market Natesto data https://seekingalpha.com/news/3446052-aytu-bio-up-12-premarket-positive-post-market-natesto-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3446052-aytu-bio-up-12-premarket-positive-post-market-natesto-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446050\" data-ts=\"1553690391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446050-acaciaminus-4-morgan-stanley-cuts-on-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia -4% as Morgan Stanley cuts on risk</a></h4><ul><li>Morgan Stanley downgrades Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications, Inc.'>ACIA</a>) from Equal-Weight to Underweight and cuts the target from $38 to $44 citing risks to customer concentration, which could become a larger issue next year.</li><li>Analyst Meta Marshall thinks ACIA \"could post meaningful beats in the next 6-9 months,\" but says investors are \"over-extrapolating earnings power\" while minimizing the risk.</li><li>ACIA shares are <font color=\"red\">down 4.2%</font> pre-market to $53.81.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446050\" data-linked=\"Acacia -4% as Morgan Stanley cuts on risk\" data-tweet=\"$ACIA - Acacia -4% as Morgan Stanley cuts on risk https://seekingalpha.com/news/3446050-acaciaminus-4-morgan-stanley-cuts-on-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3446050-acaciaminus-4-morgan-stanley-cuts-on-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446048\" data-ts=\"1553690214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IAG\" target=\"_blank\">IAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446048-iamgold-makes-new-discovery-cot-gold-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IAMGOLD makes new discovery at Côté gold project</a></h4><ul><li>IAMGOLD (NYSE:<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a>) <font color=\"green\">+3.2%</font> pre-market after announcing a <a href=\"https://seekingalpha.com/pr/17456078-iamgold-reports-new-gold-discovery-cote-gold-project-ontario\" target=\"_blank\">new gold discovery</a> at the Côté project in Ontario.</li><li>IAG says the latest drilling results confirm the discovery of a new zone of  mineralization located about 1.5 km northeast of the Côté gold deposit, which has proven and probable mineral reserves totaling 7.3M oz. of contained gold, and measured and indicated resources of 10M oz. of  contained gold.</li><li>IAG says the discovery represents the most significant drill intercepts  of continuous gold mineralization so far encountered outside of the Côté deposit on the project mineral holdings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446048\" data-linked=\"IAMGOLD makes new discovery at Côté gold project\" data-tweet=\"$IAG - IAMGOLD makes new discovery at Côté gold project https://seekingalpha.com/news/3446048-iamgold-makes-new-discovery-cot-gold-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3446048-iamgold-makes-new-discovery-cot-gold-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446047\" data-ts=\"1553690023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNF\" target=\"_blank\">UNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446047-unifirst-beat-estimates-in-q2-and-raised-fy2019-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UniFirst beat estimates in Q2 and raised FY2019 guidance</a></h4><ul><li>Unifirst (NYSE:<a href='https://seekingalpha.com/symbol/UNF' title='UniFirst Corporation'>UNF</a>) reports Core Laundry revenue rose 4.1% to $394.41M in <a href=\"https://seekingalpha.com/pr/17456578-unifirst-announces-financial-results-second-quarter-fiscal-2019\" target=\"_blank\">Q2</a>.</li><li>Specialty Garments segment revenue increased 10.1% to $29.75M</li><li>First Aid segment revenue grew 0.2% to $13.33M.</li><li>Gross margin rate slipped 110 bps to 35.6%.</li><li>Operating margin rate improved 430 bps to 14.3%.</li><li>Segment earnings: Core Laundry operations: $59.11M (+55.2%); Specialty Garment: $2.24M (-20.2%); First Aid: $1.1M (+2.8%).</li><li>During the quarter, the Company repurchased 45K common shares at an average share price of $139.57.</li><li><b>FY2019 Guidance</b>: Revenues: $1.785B to $1.795B; Diluted EPS: $7.65 to $7.90.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446028-unifirst-beats-0_15-beats-revenue\" target=\"_blank\">UniFirst beats by $0.15, beats on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446047\" data-linked=\"UniFirst beat estimates in Q2 and raised FY2019 guidance\" data-tweet=\"$UNF - UniFirst beat estimates in Q2 and raised FY2019 guidance https://seekingalpha.com/news/3446047-unifirst-beat-estimates-in-q2-and-raised-fy2019-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3446047-unifirst-beat-estimates-in-q2-and-raised-fy2019-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446043\" data-ts=\"1553689799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOP\" target=\"_blank\">APOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446043-cellect-bio-up-17-premarket-on-positive-apograft-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellect Bio up 17% premarket on positive ApoGraft data</a></h4><ul><li>Thinly traded nano cap Cellect Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) is up <font color=\"green\">17%</font> premarket on modestly higher volume in reaction to positive <a href=\"https://seekingalpha.com/pr/17456491-cellect-announces-positive-phase-ii-mid-study-results-apograft-technology\" target=\"_blank\">preliminary results</a> from a Phase 1/2 clinical trial evaluating its ApoGraft stem cell selection technology in patients undergoing stem cell transplantation.</li><li>Eight of 12 planned participants have been enrolled. Six have completed the 180-day follow-up.</li><li>All patients receiving ApoGraft-processed stem cells experienced engraftment in a time frame similar to standard of care &#40;SOC&#41;. The mean time to neutrophil engraftment was 15.8 days. The mean time to platelet engraftment was 16.9 days, both on par with SOC.</li><li>No safety signals were observed. 11 serious adverse events were reported in six patients, none related to ApoGraft.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397291-cellects-apograft-shows-encouraging-action-early-stage-study-shares-1-percent\" target=\"_blank\">Cellect's ApoGraft shows encouraging action in early-stage study; shares up 1%</a> (Oct. 15, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3446043\" data-linked=\"Cellect Bio up 17% premarket on positive ApoGraft data\" data-tweet=\"$APOP - Cellect Bio up 17% premarket on positive ApoGraft data https://seekingalpha.com/news/3446043-cellect-bio-up-17-premarket-on-positive-apograft-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3446043-cellect-bio-up-17-premarket-on-positive-apograft-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446042\" data-ts=\"1553689749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCO\" target=\"_blank\">ARCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446042-arcos-doradosplus-5-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcos Dorados +5% after earnings</a></h4><ul> <li>Arcos Dorados (NYSE:<a href='https://seekingalpha.com/symbol/ARCO' title='Arcos Dorados Holdings Inc.'>ARCO</a>) reports systemwide comparable sales increased 7.5% in <a href=\"https://seekingalpha.com/pr/17456494-arcos-dorados-reports-fourth-quarter-and-full-year-2018-financial-results\" target=\"_blank\">Q4</a>. Total revenue was up 9.1% on a constant currency basis.</li> <li>Adjusted EBITDA was down 2.2% to $87.1M (+13% constant currency). Net income fell 70% to $19M, due primarily to costs from the company's redevelopment initiative.</li> <li>The restaurant company ended the quarter with 968 units vs. 929 units a year ago.</li> <li>Arcos management says loyalty to the McDonald's brand is growing as its rolls out the Experience of the Future concept across restaurants.</li> <li>Shares of ARCO are <font color=\"green\">up 4.95%</font> premarket to $7.85.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3446032-arcos-dorados-holdings-misses-revenue\" target=\"_blank\">Arcos Dorados Holdings misses on revenue</a> (March 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446042\" data-linked=\"Arcos Dorados +5% after earnings\" data-tweet=\"$ARCO - Arcos Dorados +5% after earnings https://seekingalpha.com/news/3446042-arcos-doradosplus-5-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3446042-arcos-doradosplus-5-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446041\" data-ts=\"1553689722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446041-lumentumplus-2-morgan-stanley-sees-2019-upsides\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumentum +2% as Morgan Stanley sees 2019 upsides</a></h4><ul><li>Morgan Stanley upgrades Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) from Equal-Weight to Overweight saying that the rest of the year \"presents more opportunity for upside. \"</li><li>Analyst Meta Marshall expects LITE to benefit on its data center business exit and as Oclaro-related synergies start to be recognized.</li><li>LITE shares are <font color=\"green\">up 2%</font> pre-market to $54.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446041\" data-linked=\"Lumentum +2% as Morgan Stanley sees 2019 upsides\" data-tweet=\"$LITE - Lumentum +2% as Morgan Stanley sees 2019 upsides https://seekingalpha.com/news/3446041-lumentumplus-2-morgan-stanley-sees-2019-upsides?source=tweet\" data-url=\"https://seekingalpha.com/news/3446041-lumentumplus-2-morgan-stanley-sees-2019-upsides\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446038\" data-ts=\"1553689337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446038-onplus-2_4-goldman-cites-improved-position\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ON +2.4% as Goldman cites improved position</a></h4><ul><li>Goldman Sachs upgrades ON Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) from Neutral to Buy and raises the target from $22 to $26 citing an improved position on secular growth opportunities in data center and telecom chips, ADAS camera sensors, and auto-related chips.</li><li>Analyst Mark Delaney says ON could still face cyclical pressures, but sees evidence \"ON is improving cycle to cycle\" and thinks the semi cycle risks are priced into the stock.</li><li>ON shares are <font color=\"green\">up 2.4%</font> pre-market to $21.51.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446038\" data-linked=\"ON +2.4% as Goldman cites improved position\" data-tweet=\"$ON - ON +2.4% as Goldman cites improved position https://seekingalpha.com/news/3446038-onplus-2_4-goldman-cites-improved-position?source=tweet\" data-url=\"https://seekingalpha.com/news/3446038-onplus-2_4-goldman-cites-improved-position\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446036\" data-ts=\"1553689074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446036-slowing-trend-seen-ollies-bargain-outlet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Slowing trend seen at Ollie&#39;s Bargain Outlet</a></h4><ul> <li>Wells Fargo digs into the \"somewhat disappointing\" Q4 report from Ollie's Bargain Outlet Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a>).</li> <li>\"The post-Holiday comps slowed by more than expected and commentary on Q1 suggests this trend has continued into 2019,\" notes the firm.</li> <li>\"While Q4 closes out a generally impressive 2018 for the company, 2019 looks to be setting up as a year of slower (although still solid) growth with some potential for a top line disappointment on a tough toy comparison. We believe risk / reward on the name remains balanced at this time and maintain our Market Perform rating.\"</li> <li>Shares of Ollie's are <font color=\"red\">down 3.14%</font> in premarket trading to $79.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445881-ollies-sheds-5-percent-light-guidance\" target=\"_blank\">Ollie's sheds 5% after light guidance</a> (March 26)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446036\" data-linked=\"Slowing trend seen at Ollie&#39;s Bargain Outlet\" data-tweet=\"$OLLI - Slowing trend seen at Ollie&#39;s Bargain Outlet https://seekingalpha.com/news/3446036-slowing-trend-seen-ollies-bargain-outlet?source=tweet\" data-url=\"https://seekingalpha.com/news/3446036-slowing-trend-seen-ollies-bargain-outlet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446031\" data-ts=\"1553688591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RL\" target=\"_blank\">RL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446031-wells-fargo-expects-to-line-momentum-ralph-lauren\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo expects to-line momentum at Ralph Lauren</a></h4><ul> <li>Wells Fargo calls Ralph Lauren (NYSE:<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a>) a \"rare standout\" in the apparel sector.</li> <li>Analyst Ike Bochurow points to the top-line growth at Ralph Lauren to go along with the margin improvement.</li> <li>\"We see a return to sustainable top-line growth driving valuation higher, as a \u201ccleaned up\u201d RL with visible top-line drivers in place (primarily China, Europe and global digital) is set to sustain upward revisions,\" writes Bochurow.</li> <li>WF upgrades Ralph Lauren to Outperform from Market Perform and sets a price target of $150.</li> <li>Shares of Ralph Lauren are <font color=\"green\">up 0.82%</font> premarket to $123.27.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3446031\" data-linked=\"Wells Fargo expects to-line momentum at Ralph Lauren\" data-tweet=\"$RL - Wells Fargo expects to-line momentum at Ralph Lauren https://seekingalpha.com/news/3446031-wells-fargo-expects-to-line-momentum-ralph-lauren?source=tweet\" data-url=\"https://seekingalpha.com/news/3446031-wells-fargo-expects-to-line-momentum-ralph-lauren\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446030\" data-ts=\"1553688501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCSC\" target=\"_blank\">FCSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446030-fibrocell-down-18-premarket-on-updated-fcxminus-007-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrocell down 18% premarket on updated FCX-007 data</a></h4><ul><li>Thinly traded nano cap Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) slips <font color=\"red\">18% </font>premarket on light volume on the heels of <a href=\"https://seekingalpha.com/pr/17456436-fibrocell-announces-positive-feedback-type-b-end-phase-2-meeting-fda-phase-3-clinical-trial\" target=\"_blank\">updated results</a> from a Phase 1/2 clinical trial evaluating gene therapy FCX-007 in adults with recessive dystrophic epidermolysis bullosa &#40;RDEB&#41;, an inherited disorder characterized by fragile blistering skin. Investors appear disappointed with the data despite the similarity with the results <a href=\"https://seekingalpha.com/news/3358296-fibrocells-gene-therapy-fcxminus-007-shows-positive-effect-rdeb-study-shares-4-percent\" target=\"_blank\">announced </a>in May 2018.</li><li>Five patients received a single injection of FCX-007. At week 4, all wounds (n=8/8) closed at least 50%. The percentage dropped to 88% (n=7/8) at week 12. The proportions were 67% and 66% at week 25 and week 52, respectively, but these were based on only three wounds.</li><li>The results at week 12 were significantly better than placebo. 88% (n=7/8) of treated wounds closed at least 50% compared to 29% (n=2/7) for placebo. The proportion of treated wounds that closed at least 75% was 75% (n=6/8) versus 14% (n=1/7) for placebo. 63% (n=5/8) of treated wounds completely closed versus 0% (n=0/7) for control.</li><li>The first pediatric patient, the sixth participant, recently completed dosing.</li><li>The company recently met with the FDA to clarify the design of a Phase 3 study. The open-label trial, named DEFI-RDEB, will enroll 15 - 20 subjects and will assess two doses of FCX-007. The primary endpoint will be the complete wound closure rate at week 12 compared to untreated wounds (comparison will be between paired wounds). The study should launch next quarter.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446030\" data-linked=\"Fibrocell down 18% premarket on updated FCX-007 data\" data-tweet=\"$FCSC - Fibrocell down 18% premarket on updated FCX-007 data https://seekingalpha.com/news/3446030-fibrocell-down-18-premarket-on-updated-fcxminus-007-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3446030-fibrocell-down-18-premarket-on-updated-fcxminus-007-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446015\" data-ts=\"1553687841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446015-axsomes-axsminus-05-breakthrough-therapy-for-mdd-shares-up-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome&#39;s AXS-05 a Breakthrough Therapy for MDD; shares up 14% premarket</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17456394-axsome-therapeutics-receives-fda-breakthrough-therapy-designation-axsminus-05-treatment-major\" target=\"_blank\">granted</a> Breakthrough Therapy designation to Axsome Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) AXS-05 for the treatment of major depressive disorder &#40;MDD&#41;.</li><li>AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li>  <li>Shares are up <font color=\"green\">14%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3446015\" data-linked=\"Axsome&#39;s AXS-05 a Breakthrough Therapy for MDD; shares up 14% premarket\" data-tweet=\"$AXSM - Axsome&#39;s AXS-05 a Breakthrough Therapy for MDD; shares up 14% premarket https://seekingalpha.com/news/3446015-axsomes-axsminus-05-breakthrough-therapy-for-mdd-shares-up-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3446015-axsomes-axsminus-05-breakthrough-therapy-for-mdd-shares-up-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3446012\" data-ts=\"1553687525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTSI\" target=\"_blank\">MTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3446012-macomminus-3_9-on-goldman-cut-for-hurdles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MACOM -3.9% on Goldman cut for &quot;hurdles&quot;</a></h4><ul><li>Goldman Sachs downgrades MACOM Technology Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a>) from Neutral to Sell citing a \"higher bar\" in meeting consensus estimates in the second half of 2019.</li><li>The firm expects revenue growth to improve next year but sees \"hurdles to achieving the magnitude\" of improvement assumed in Street estimates.</li><li>Goldman also cites MTSI's \"premium valuation\" as the most expensive stock in the firm's coverage based on 2020 P/E ratios and other metrics.</li><li>Related: Last month, MACOM <a href=\"https://seekingalpha.com/news/3430139-trade-tensions-weigh-macom-guidance-mtsi-minus-16-percent\" target=\"_blank\">reported Q1 results</a> with a hefty Q2 guidance miss the company attributed to macro and trade-related \"cross currents\" that MTSI expected to rebound in H2.</li><li>MTSI <font color=\"red\">drops 3.9%</font> pre-market to $17.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3446012\" data-linked=\"MACOM -3.9% on Goldman cut for &quot;hurdles&quot;\" data-tweet=\"$MTSI - MACOM -3.9% on Goldman cut for &quot;hurdles&quot; https://seekingalpha.com/news/3446012-macomminus-3_9-on-goldman-cut-for-hurdles?source=tweet\" data-url=\"https://seekingalpha.com/news/3446012-macomminus-3_9-on-goldman-cut-for-hurdles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445998\" data-ts=\"1553686359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TITN\" target=\"_blank\">TITN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445998-on-titan-machinerys-q4-mixed-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Titan Machinery&#39;s Q4 mixed results</a></h4><ul><li>Titan Machinery (NASDAQ:<a href='https://seekingalpha.com/symbol/TITN' title='Titan Machinery Inc.'>TITN</a>) reports equipment revenue rose 7.8% to $283.99M in <a href=\"https://seekingalpha.com/pr/17456341-titan-machinery-inc-announces-results-fiscal-fourth-quarter-full-year-ended-january-31-2019\" target=\"_blank\">Q4</a>.</li><li>Parts revenue grew 7.8% to $43.87M.</li><li>Service revenue fell 1.4% to $18.83M.</li><li>Segment revenue: Agriculture: $223.27M (+9.2%); Construction: $86.43M (+2.5%); International: $49.95M (+2.9%).</li><li>Gross margin rate increased 10 bps to 15.5%.</li><li>Adjusted EBITDA up 9.8% to $6.75M.</li><li>Operating expense rate +10 bps to 15%.</li><li><b>FY2020 Guidance</b>: Agriculture sales: flat; Construction sales: +0% to +5%; International sales: +10% to +15%; Diluted EPS: $0.50 to $0.70; Adjusted EPS: $0.75 to $0.95.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445971-titan-machinery-misses-0_05-beats-revenue\" target=\"_blank\">Titan Machinery misses by $0.05, beats on revenue</a> (March 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445998\" data-linked=\"More on Titan Machinery&#39;s Q4 mixed results\" data-tweet=\"$TITN - More on Titan Machinery&#39;s Q4 mixed results https://seekingalpha.com/news/3445998-on-titan-machinerys-q4-mixed-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3445998-on-titan-machinerys-q4-mixed-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}